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ABSTRACT 
Major histocompatibility complex molecules (MHCII) are cell surface glycoproteins that 
present extracellular antigens to CD4+ T lymphocytes and initiate adaptive immune responses. 
Apart from their protective role, overexpression of MHCII contributes to autoimmune disorders 
where the immune system attacks our own tissues. Autoimmune diseases are characterized by 
self-reactive responses to autoantigens, promoting tissue damage, inflammation mediated by 
proinflammatory cytokines, autoreactive lymphocytes, and autoantibodies. MHCII molecules are 
tightly regulated at the level of transcription by Class II transactivator (CIITA). CIITA associates 
with an enhanceosome complex at MHCII promoters and regulates the expression of MHCII. It 
is thus crucial to understand the regulation of CIITA expression in order to regulate MHCII in 
autoimmune diseases. Our lab has shown that the 19S ATPases of the 26S proteasome associate 
with MHCII and CIITA promoters and play important roles in gene transcription, regulate 
covalent modifications to histones, and are involved in the assembly of activator complexes in 
mammalian cells. The mechanisms by which the proteasome influences transcription remain 
unclear. Here, we define novel roles of the 19S ATPases Sug1, S7, and S6a in expression of 
CIITApIV genes. These ATPases are recruited to CIITApIV promoters and coding regions, 
interact with the elongation factor PTEFb, and with Ser5 phosphorylated RNA Pol II. Both the 
generation of CIITApIV transcripts and efficient recruitment of RNA Pol II to CIITApIV are 
negatively impacted by knockdown of 19S ATPases.  
Alternatively, inflammation is also suppressed via the Regulator of G-protein signaling 
10 (RGS10) in microglial cells which express high levels of RGS10 and promote homeostasis in 
the central nervous system. However, chronic activation of microglial cells leads to release of 
cytokines which cause neuroinflammation. Our investigation of roles played by RGS10 in 
chronically activated microglial cells indicates that RGS10 binds to promoters of IL-1β, and 
TNF-α and regulates these genes, while the molecular mechanism remains to be investigated. 
Together, our observations indicate roles for the UPS in modulating gene expression and for 
RGS10 in regulating proinflammatory cytokines in microglial cells, each of which provides 
novel therapeutic targets to combat inflammation in autoimmune and neurodegenerative 
diseases. 
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1 CHAPTER I: INTRODUCTION  
 
Inflammation in general describes the reaction of living tissues to injury. Inflammation of 
the central nervous system (CNS) is initiated by infection, brain injury, toxic metabolites or 
autoimmunity to brain tissue which activates microglial cells. Sustained activation of microglial 
cells is known as “reactive microgliosis” and leads to the recruitment of additional immune cells 
to brain tissues causing neurodegenerative conditions in the CNS (Block, Zecca et al. 2007); 
(Aloisi 1999). Acute inflammation describes the early response to infectious agents mediated by 
infiltration of neutrophils. Chronic inflammation results from stimuli that are persistent, such as 
infiltration of macrophages, lymphocytes and plasma cells. Inflammation in the CNS is the major 
cause of neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Multiple Sclerosis.  
Increasing evidence suggests that over activated microglia cells are a key causative factor for 
promoting inflammation in these diseases (Liu and Hong 2003). Indeed, microglial activation is 
the major cause of inflammation in the CNS leading to Multiple Sclerosis (Jack, Ruffini et al. 
2005) (Gao and Tsirka 2011) (Goldmann and Prinz 2013), Alzheimers (Solito and Sastre 2012) 
and Parkinson’s (Liu and Hong 2003).  
Alzheimers is the sixth leading cause of death in the United States and particularly 
individuals over the age of 65 are affected by this disease. An estimate of 5.3 million Americans 
suffer from Alzheimers, of which 200,000 are below the age of 65 and 5.1 million of which are 
over the age of 65, (Alzheimer's 2015). Alzheimers was the first neurodegenerative disease to be 
associated with the toxic effects of microglial activation (Solito and Sastre 2012) and is 
characterized by progressive impairment of memory and increased microglial activation as the 
disease progresses. Alzheimers involves accumulation of Amyloid-beta protein aggregates which 
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are toxic to the neurons (Hegde 2004) (Jung, Catalgol et al. 2009) and microglial activation. 
Activated microglia cluster at the sites of aggregated Aβ and release neurotoxic factors such as 
nitric oxide, tumor necrosis factor-alpha and superoxide, thus promoting neuroinflammation in 
the CNS (Solito and Sastre et al. 2006). Microglial cells express scavenger receptors of Class A 
or B which associate with plaques containing beta amyloid, activate inflammatory responses, and 
contribute to the pathology of Alzheimers disease (Paresce, Ghosh et al. 1996) (El Khoury, 
Hickman et al. 1996). 
Parkinsons disease is the second most common neurodegenerative disorder following 
Alzheimers; impacting 1% of the population and primarily individuals between the ages of 65 to 
69 years of age with the prevalence increasing to 3% among individuals 80 years of age 
(Nussbaum and Ellis 2003) (Tanner and Goldman 1996).  Parkinsons disease is characterized by 
loss of dopaminergic neurons and by the presence of lewy bodies within brain cells. Lewy bodies 
are formed due to accumulation of alpha-synuclein (Jung, Catalgol et al. 2009) (Hegde 2004).  
Parkinsons disease is characterized by motor dysfunction including slowness of motion, loss of 
balance and by the iniation of movements with difficulty. The damaged neurons release several 
factors such as matrix metalloproteinase 3, alpha-synuclein and neuromelanin which activate 
microglia leading to reactive oxygen species production which further cause degeneration of 
dopaminergic neurons. Hence, chronic microglial activation is an important chronic 
neuroinflammatory component that contributes to disease progression by neuronal injury, 
dysfunction and ultimately loss of neuronal cells in the CNS (Tansey, McCoy et al. 2007).   
Multiple sclerosis is another example of chronic inflammatory brain disease caused by a 
myelin-related protein that acts as an autoimmunogen and promotes accumulation of leucocytes 
in the CNS, and will be the primary disease focus of this dissertation. Multiple Sclerosis is 
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caused by a T-cell mediated immune response to MHC presentation of self brain tissues such as 
myelin basic protein, leading to dissolution of the myelin sheath around nerve axons and 
development of hard lesions in the CNS (Steinman 1996).  When CNS tissues are inflamed, the 
blood-brain barrier breaks, and autoreactive CD4+ T-cells migrate out of the blood vessels and 
into CNS tissues. Following this migration, these autoreactive T-cells may encounter CNS 
autoantigens presented by Major Histocompatibility Class II (MHCII) on microglial cells (brain 
resident macrophages), leading to inflammation caused by increased vascular permeability and 
infiltration of Th17 and Th1 cells (Frohman, Racke et al. 2006). These infiltrating T-cells secrete 
IL17 and IFN-γ cytokines which, together with autoreactive antibodies, act on myelin antigens 
leading to demyelination and interfere with neuronal function (Frohman, Racke et al. 2006, 
Trapp and Nave 2008). 
During the inflammatory response to Multiple Sclerosis, T cells are sensitized against 
myelin components in the CNS via MHCII expression of myelin peptides. The sensitized T cells 
enter the CNS and are activated by resident antigen-presenting cells, resulting in a cascade of 
inflammatory damage. Neuroinflammation promotes accumulation of soluble mediators such as 
TNF-α, IL-1, and IL-6 that cause neuronal cell damage or death (Frohman, Racke et al. 2006). 
The initial inflammatory phase is followed by demyelination and finally neurodegeneration.  One 
way to combat inflammation in Multiple Sclerosis is by regulating expression of MHCII genes, 
which is the focus of Chapter 2 of the dissertation. 
Apart from autoimmunity to myelin peptides, microglial activation in MS leads to 
damage to CNS through production of proinflammatory cytokines, free radicals and reactive 
oxygen species (Goldmann and Prinz 2013) (Benveniste 1997) (Czeh, Gressens et al. 2011) 
(Jack, Ruffini et al. 2005) (Haider, Fischer et al. 2011). Microglial cells and T lymphocytes are 
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in close proximity to each other in demyelinating and axonal injury in MS lesions, leading to 
oxidative damage to the neurons in the CNS (Hucke, Flossdorf et al. 2012) Strachan-Whaley, 
Rivest et al. 2014). Reactive microgliosis plays a major role in neuronal loss in several 
neurodegenerative diseases. The Regulator of G-protein signaling 10, RGS10, was recently 
shown to be abundantly expressed in microglial cells and to play an anti-inflammatory role in 
protecting dopaminergic neurons (Lee, McCoy et al. 2008) (Lee, Chung et al. 2012). Based on 
these studies, RGS10 may also play anti-inflammatory roles in microglial cells and additional 
roles in controlling inflammation in the CNS. Chapter 3 in this dissertation explores the ability of 
RSG10 to drive expression of proinflammatory genes in the CNS and directly contribute to CNS 
and microglial activation. 
In sum, the critial immune response genes Major Histocompatibility Complex II (MHCII) 
and the Class II Transactivator (CIITA) are key molecules involved in initiating adaptive 
immune responses. These genes are tightly regulated at the level of transcription but 
dysregulated overexpression promotes autoimmune diseases such as multiple sclerosis and 
neuroinflammatory conditions in CNS. Transcription regulation of CIITA by the 26S proteasome 
and the regulation of RGS10 in microglial cells which aids in controlling inflammation in the 
CNS will be the focus this dissertation. 
 
1.1 Transcription Regulation:  
Every organ in the human body functions distinctly based on regulated gene expression. 
Genes that are rarely needed in particular cell types are silenced at the level of promoter 
methylation (Surani 1991), while some genes that are important for cellular functions such as 
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cell structure and metabolism are transcribed constitutively (Su, Strand et al. 1988), and some 
genes that are needed only occasionally during processes such as mitosis are transcribed 
facultatively (Delcuve, Rastegar et al. 2009). The remaining genes are activated by stimulation 
with signaling molecules such as hormones, growth factors, cytokines and environmental factors 
such as stress (Maniatis, Goodbourn et al. 1987) (Weake and Workman 2010).  
Transcription is a tightly regulated cellular process involving multiple proteins which 
must be recruited to the promoter region of genes in order to regulate their expression. In 
addition, gene expression is regulated at five stages, pre-initiation, initiation, promoter clearance, 
elongation and termination and requires specific sequences such as the TATA box, GC box, and 
CAAT box, and transcription factors such as TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH. 
These factors bind to promoter regions of genes and form the preinitiation complex (PIC) 
(Buratowski 1994) (Cox, Kays et al. 1998). TFIIA interacts with the TATA-binding protein 
(TBP) subunit of TFIID and also interacts with TFIIB (Solow, Salunek et al. 2001) (Nikolov, 
Chen et al. 1995). TFIID consists of TBP and 16 TBP-associated factors (Timmers, Meyers et al. 
1992). TFIID in complex with TFIIA and TFIIB, binds at the TATA box at the promoter region 
of genes (Lee and Young 2000). TFIIE binds single stranded DNA and helps in maintaining the 
transcription bubble (Okamoto, Yamamoto et al. 1998). TFIIF stabilizes PIC and recruits RNA 
Pol II to the promoter region of DNA and initiates transcription (Tan, Conaway et al. 1995) 
(Deng and Roberts 2007). In eukaryotes RNA pol II transcribes mRNA from DNA templates in 
all protein coding genes. TFIIH includes cyclin dependent kinase (CDK7) responsible for 
phosphorylation of serine residues with the C-terminal domain of RPB1 subunit (Kershnar, Wu 
et al. 1998) (Zurita and Merino 2003). RPB1 is the largest subunit among 12 subunits of RNA 
Pol II and contains 52 repeats of the heptapeptide sequence (Tyr-Ser-Pro-Thr-Ser-Pro-Ser 
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YSPTSPS) at its C-terminal domain which are modified to regulate transcription (Barron-Casella 
and Corden 1992) (Corden 1990). The serines within the heptapeptide sequence are 
phosphorylated and govern the activity of the RNA Pol II complex. Serine 5 phosphorylation 
leads to activation of initiation and Serine 2 phosphorylation promotes transcript elongation 
(Buratowski 2009) (Corden, Cadena et al. 1985) (Heidemann, Hintermair et al. 2013). 
Once initiated, the PIC complex is further controlled by positive and negative 
transcription factors which regulate gene expression. The switch from transcriptional initiation to 
elongation is dynamic and is controlled by interactions between positive and negative 
transcription factors. RNA Pol II is paused by negative transcription elongation factors (NTEF’s) 
(Natarajan, Schiralli Lester et al. 2013) (Sims, Belotserkovskaya et al. 2004). Transcription 
elongation involves proteins which associate with RNA pol II to facilitate its progression by 
transiently modifying the chromatin template. These protein factors overcome the barriers 
imposed by chromatin and traverse through the nucleosome structures in order to promote proper 
gene expression. Elongation factors such as Positive transcription elongation factor (PTEF-b), 
DRB sensitivity inducing factor (DSIF), Negative elongation factor (NELF) and the C-terminal 
domain CTD of RNA pol II mediate the elongation step. The positive transcription elongation 
factor (PTEFb) is recruited to the NTEF complex where it phosphorylates the CTD of RNA Pol 
II and NTEF and promotes elongation (Sims, Belotserkovskaya et al. 2004) (Peterlin and Price 
2006) (Ivanov, Kwak et al. 2000). The phosphorylation state of the CTD changes through the 
transcription cycle and is important for recruiting appropriate regulatory factors during each 
stage of transcription (Dahmus 1996). 
In the Initiation stage RPB1 is hypophosphorylated. Upon transition from initiation to 
early elongation, the CTD becomes phosphorylated on serine 5 and on serine 7 by cyclin 
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dependent kinase (CDK7) of TFIIH that facilitates escape from the promoter. Initial transcription 
is non-productive until the formation of 8 to 9 base pairs of nascent mRNA from the DNA 
template. Later in the elongation stage, serine 2 of CTD becomes phosphorylated by cyclin 
dependent kinase 9 (CDK9) of positive transcription elongation factor b (PTEF-b) which 
stimulates productive elongation (Peterlin and Price 2006). PTEFb exists as an active and 
inactive complex (Yang, Zhu et al. 2001) (Nguyen, Kiss et al. 2001). PTEF-b is a complex 
consisting of Cyclin-T and CDK9, hexamethylene bisacetamide inducible protein (Hexim-1) and 
7SK RNA (Price 2000). Upon transcription initiation, PTEF-b dissociates from Hexim-1 and 
7SK RNA and the active form is recruited to the transcription initiation complex. CDK-9 then 
phosphorylates serine 2 of RNA pol II CTD and transits from initiation into productive 
elongation. The regulation of post-initiation stages is important because genes that are 
successfully initiated cannot produce productive transcripts due to defects in transcription 
elongation. Additional regulation through pausing of RNA Pol II allows the replacement of 
initiation factors with molecules required for transcriptional elongation and RNA processivity 
(Nechaev and Adelman 2011). 
 
1.2 Major Histocompatibility Complex: 
Humans are constantly exposed to pathogens in the environment which are fought by our 
immune system. The immune system is composed of two arms: the innate immune response 
which is non-specific and provides a first line of defense against pathogens and the adaptive 
immune response which is highly specific, although which has a delayed response against 
pathogens (Medzhitov and Janeway 1997). The cells of the adaptive immune response develop 
memory against invading pathogens and thus provide long term memory and also long term 
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protection. Hence specificity and long term memory are important characteristics of adaptive 
immune responses (Hoebe, Janssen et al. 2004). 
 
Major Histocompatibility Complex (MHC) molecules are cell surface glycoproteins 
involved in antigen presentation to lymphocytes which protect us against invading pathogens. 
MHCII is thus an important regulator of adaptive immune responses. The tight regulation of 
MHCII genes is important because overexpression of MHCII molecules leads to the 
development of autoimmune disorders including Multiple Sclerosis and Rheumatoid Arthritis 
(Swanberg, Lidman et al. 2005). Foreign antigen is presented to T lymphocytes by MHCII 
molecules expressed on the surface of antigen presenting cells (APCs) to initiate an adaptive 
immune response. Autoimmune responses are initiated by immune responses to self antigens and 
give rise to autoreactive effector T-cells and autoantibodies which in turn destroy the self tissue. 
 
1.3 Adaptive Immune Response: 
Effective adaptive immune systems involve various immune cells such as lymphocytes 
and antigen presenting cells and fine regulation of immune proteins. One of the major immune 
proteins are MHC Class I and MHC Class II molecules (Klug, Miller et al. 2009). MHC I present 
antigens to CD8+ T lymphocytes and MHC II presents to CD4+ T Lymphocytes. CD4+ T cells 
recognize peptides presented by MHCII and help in the activation of antigen presenting cells 
(Matheux and Villard 2004) (Steinitz, van Helden et al. 2012).  CD8+ T cells recognize peptides 
presented by MHCI and kill infected cells (Rock 1996) (Foss 2002). Lymphocytes originate in 
primary lymphoid organs including bone marrow and thymus and, following development, enter 
into secondary lymphoid organs such as the spleen and lymph nodes. Activated B lymphocytes 
may give rise to plasma cells which produce antibodies, which either alone, or in combination 
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with activated T lymphocytes, aid in pathogen clearance (Glimcher and Kara 1992). Both 
activated B and T lymphocytes may also produce a subset of memory cells which persist after 
clearing of infection and promote quick immune responses when re-exposed to the same 
pathogen. The tight regulation of MHCII genes is important because overexpression of MHCII 
molecules leads to the development of autoimmune diseases (Swanberg, Lidman et al. 2005) and 
MHCII is also an important regulator of initiating the adaptive immune response, so MHCII 
expression is tightly regulated at the level of transcription (Benoist and Mathis 1990) (Glimcher 
and Kara 1992) (Figure 1.2).  
 
1.4 MHCII Transcription regulation: 
MHCII molecules are constitutively expressed on antigen presenting cells including 
macrophages, B cells, and dendritic cells and can be induced with the proinflammatory cytokine 
interferon gamma (IFN-γ) on all nucleated cells (Weber and Rosenberg 1988, Kaufman, 
Salomonsen et al. 1994) in order to aid in the development of adaptive immune responses 
(Glimcher and Kara 1992, Matheux and Villard 2004). As previously indicated, activation of 
CD4+ T cells is required for cell mediated and antibody mediated immune responses (Glimcher 
and Kara 1992). Thus, the inducible nature of the MHCII complex makes it an ideal system for 
studies of transcriptional regulation. 
MHCII gene expression is tightly regulated by an interplay of several transcription 
factors which bind to conserved regulatory elements in the MHCII promoter region. The MHCII 
promoter region consists of three conserved sequences termed the X1 box, X2 box and Y box 
(Reith and Mach 2001) (Benoist and Mathis 1990) which are recognized by DNA binding 
transcription factors. The X1 box is bound by Regulatory factor X (RFX) (Ting and Trowsdale 
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2002) (Masternak, Barras et al. 1998) (Steimle, Durand et al. 1995), the X2 box is bound by the 
cAMP response element binding protein (CREB) (Moreno, Beresford et al. 1999), and the Y box 
is bound by the nuclear factor Y (NFY) (Mantovani 1999) to form the enhanceosome complex 
(Ting and Trowsdale 2002) (Figure 1.1).  
In addition to these, other factors such as TATA binding protein (TBP), TATA associated 
factors (TAFs), and histone modifying enzymes are found at the MHCII promoter where they 
combine to form the MHCII enhanceosome complex (Masternak, Muhlethaler-Mottet et al. 
2000). Once assembled, the enhanceosome complex recruits the class II transactivator (CIITA) 
(Steimle, Otten et al. 1993) (Muhlethaler-Mottet, Otten et al. 1997) (Masternak, Muhlethaler-
Mottet et al. 2000). CIITA does not bind to DNA directly but binds to the pre-assembled 
enhanceosome complex (Fontes, Jiang et al. 1997) (Zhu, Linhoff et al. 2000) (Jabrane-Ferrat, 
Nekrep et al. 2003). CIITA promotes accessibility of the MHCII promoter by recruiting histone 
modifying enzymes such as histone acetyl transferases CBP/p300 (HATs) (Drozina, Kohoutek et 
al. 2005) (Wright and Ting 2006), histone deacetylases (HDACs), and histone methyl 
transferases (HMTs), leading to greater transcription efficiency which then drives the initiation 
of MHCII gene transcription. Also cyclin dependent kinases (CDKs), which phosphorylate the 
C-terminal domain of RNA polymerase II, are recruited in CIITA dependent fashion and 
promote MHC class II gene transcription (Spilianakis, Kretsovali et al. 2003). However 
elongation is paused by the presence of negative transcription elongation factor (N-TEF) DRB- 
sensitive inducing factor (DSIF) (Kanazawa and Peterlin 2001) (Peterlin and Price 2006). CIITA 
binds to the CycT1 subunit of positive transcription elongation factor b complex which is also 
recruited to MHC class II promoter (Kanazawa, Okamoto et al. 2000). The CDK9 subunit of 
PTEFb phosphorylates NTEF, releasing the paused complex and promoting elongation (Oven, 
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Brdickova et al. 2007).  These are crucial steps in the initiation of MHC class II transcription and 
each plays an important role in initiating adaptive immune responses. 
 
1.5 Class II Transactivator (CIITA): 
CIITA is a non-DNA binding cofactor which is constitutively expressed in antigen 
presenting cells and is cytokine-inducible in other nucleated cell types (Masternak, Muhlethaler-
Mottet et al. 2000). CIITA is the regulator for MHC II gene expression (Mach, Steimle et al. 
1996) and, in order to maintain tight regulation of MHC II, CIITA is also tightly regulated at the 
level of transcription (Ting and Trowsdale 2002). CIITA transcription is regulated in a cell 
specific manner driven by four distinct promoters I, II, III, IV (Figure 1.3), each promoter 
yielding different CIITA isoform that will have unique first exons. Specific isoform expression is 
determined by the type of the cell in which CIITA is found and by the cytokine that stimulates 
CIITA production (Muhlethaler-Mottet, Otten et al. 1997).  
Promoter I (pI) is expressed in dendritic cells and macrophages (Muhlethaler-Mottet, 
Otten et al. 1997). Promoter II (pII) is not well conserved amongst different species and is 
considered to be inactive (Muhlethaler-Mottet, Otten et al. 1997). Promoter III is expressed in B 
cells, and can also be enhanced by IFN-γ stimulation (Piskurich, Gilbert et al. 2006). Promoter 
IV is expressed in cytokine induced nucleated cells (Muhlethaler-Mottet, Otten et al. 1997). 
Upon IFN-γ stimulation, CIITApIV is transcribed, translated and is recruited to the MHCII 
preinitiation complex which then drives the transcription of MHCII genes (Steimle, Otten et al. 
1993, Mach, Steimle et al. 1996). IFN- γ induction of MHC II parallels with CIITA expression in 
stimulated nucleated cells (Morris, Beresford et al. 2002) (Muhlethaler-Mottet, Di Berardino et 
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al. 1998). Activation of CIITApIV is initiated when IFN-γ binds to interferon-γ receptor and 
occurs via the Janus kinase signal transducer and activator of transcription (JAK-STAT) signal 
transduction pathway (Figure 1.4) (Piskurich, France et al. 1993) (Piskurich, Gilbert et al. 2006). 
IFN-γ binds to its receptor and initiates the kinase function of JAK1, JAK2, which 
autophosphorylates itself. The STAT protein then binds to phosphorylated receptor and once 
phosphorylated, STAT-1 translocates to the nucleus and binds to CIITA isoform IV. CIITApIV 
has conserved elements such as the gamma activating sequence (GAS) box which is bound by 
signal transducer and activator of transcription STAT-1 (Muhlethaler-Mottet, Di Berardino et al. 
1998), and an interferon stimulated response elements (ISRE) which binds to interferon 
regulatory factors (IRF-1) (Piskurich, Linhoff et al. 1999) (Wright and Ting 2006) (Piskurich, 
France et al. 1993) (Piskurich, Youngman et al. 1997), and constitutively expressed transcription 
factor upstream stimulating factor 1 (USF-1) which bind to E-box (Piskurich, Linhoff et al. 
1999) (Pattenden, Klose et al. 2002) (Figure 1.3). In addition to binding of transcription factors, 
loosening of chromatin structure by histone acetylation increases the accessibility of CIITApIV 
(Wright and Ting 2006) (Sterner and Berger 2000). 
However the regulation of CIITA is less well understood (Chang, Fontes et al. 1994). The 
unique ability of CIITA to regulate MHCII genes makes CIITA a critical player in regulating 
adaptive immune responses in the cell. Thus, studying the regulation of cytokine dependent 
CIITApIV expression will aid in development of treatment for diseases in which MHCII 
expression is defective. The studies within this dissertation will be a milestone in MHCII 
pathogenesis and have potential in developing therapeutic targets for regulating adaptive immune 
response. 
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1.6 The 26S Proteasome 
The 26S proteasome is a non-lysosomal organelle which aids in degradation of damaged 
and unwanted cellular proteins (Hochstrasser 1996, Ciechanover 2009). The 26S is a 2.5 MDa 
multiprotein complex purified and was characterized from rabbit reticulocyte lysate (Hough, 
Pratt et al. 1986). The 26S proteasome is known to play roles in transcription initiation and in 
elongation of genes by controlling the half life of various transcription factors. Recent 
observations indicate subunits of the proteasome are essential for transcription regulation of 
genes independent of their roles in protein degradation (Ferdous, Kodadek et al. 2002) (Greer, 
Zika et al. 2003) (Bhat and Greer 2011) (Durairaj and Kaiser 2014). Research in our lab has 
shown that the subunits of the UPS are necessary for transcriptional regulation of MHCII genes 
(Bhat, Turner et al. 2008) (Koues, Dudley et al. 2008, Koues, Dudley et al. 2009) (Truax, Koues 
et al. 2010). The role of the proteasomal subunits S7, Sug1, S6a in transcription of MHCII and 
CIITApIV will be further described in Chapter 2. 
  
The 26S proteasome consists of two distinct sub-complexes: the 19S regulatory particle 
(19S RP) and the 20S catalytic particle (20S CP).  These two subunits can exist independently in 
both nucleus and cytoplasm (Peters, Franke et al. 1994). The 19S regulatory particle in turn 
consists of a 19S lid and a 19S base. The 19S lid is composed of 9 non-ATPase subunits: 
regulatory particle non-ATPase (Rpn 3), Rpn 5-9, Rpn 11-12, and Rpn 13. The 19S base consists 
of a hexameric ring of AAA ATPases (S4, S7, S6a, S10b, S6b, Sug1), and four non- ATPase 
subunits (S1, S2, S5a, S5b) (Beck, Unverdorben et al. 2012, da Fonseca, He et al. 2012). The 
19S ATPases exist as heterodimers S6a-S10b, S7-S4 and S6b-Sug1 (Tomko and Hochstrasser 
2011) (Richmond, Gorbea et al. 1997) (Adams 2003) (Figure 1.6). The 20S catalytic particle is a 
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barrel-shaped complex composed of four heptameric rings of either α or β subunits stacked in a 
αββα conformation (Gorbea, Taillandier et al. 1999). The 20S core particle is capped on one or 
both ends by 19S regulatory particles The base ATPases contain a C-terminal hydrophobic 
tyrosine X motif that docks into the pockets of the α rings of the 20S (Smith, Chang et al. 2007). 
  
In the presence of ATP, the 19S regulatory particle associates with the 20S catalytic core 
on both sides to form the 26S proteasome, allowing for the recognition of polyubiquitinated 
substrates marked for degradation (Coux, Tanaka et al. 1996, Gonzalez, Delahodde et al. 2002). 
The 19S regulatory particle recognizes the ubiquitin chains on targeted proteins, cleaves the 
chains, unfolds the protein, and directs the unfolded protein to the 20S core for degradation 
(Coux, Tanaka et al. 1996, Strickland, Hakala et al. 2000) (Figure 1.5). 
  
It is well established that polyubiquitinated proteins are targeted for degradation by the 
26S proteasome. The 76 amino acid protein ubiquitin was initially described as a protein 
modification, which is covalently attached to lysine residues of target molecules (Ciechanover 
1998) (Zhang, Wang et al. 2004) (Taylor and Jobin 2005) (Xu and Peng 2006). Ubiquitin 
contains seven lysine residues (K-6, K-11, K-27, K-33, K-48, K-63) and proteins are marked for 
proteasomal degradation by polyubiquitination via K-48 modification. (Thrower, Hoffman et al. 
2000) (Finley, Sadis et al. 1994) (Kim, Kim et al. 2007) (Ciechanover 1998) (Ciechanover and 
Ben-Saadon 2004). Chains of four ubiquitin molecules are necessary for recognition and 
degradation by the 26S proteasome (Ciechanover 1998) (Conaway, Brower et al. 2002). The 
result of protein degradation is cleaved peptides with an average length of 8-12 amino acids and 
free ubiquitin, which can be recycled. Through these mechanisms the 26S proteasome eliminates 
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a variety of unwanted or misfolded proteins and thus regulates many important cellular processes 
(Hilt and Wolf 1996) (He, Qi et al. 1998).  
 
1.7 Role of 26S Proteasome in Transcription 
Previous work has demonstrated in yeast that 19S ATPase Rpt6, the yeast homolog of 
mammalian Sug1 has been responsible for recruitment of SAGA, a HAT (histone 
acetyltransferase) to the promoter region of yeast genes. The lack of Rpt6 results in decreased 
recruitment of SAGA and a correspondingly lower acetylated histone H3, indicating the 
importance of Rpt6 in recruiting HATs to promoter regions. (Lee, Ezhkova et al. 2005). Rpt6 
also mediates the recruitment of transcription factors to TBP and binds to actively transcribing 
genes (Gonzalez, Delahodde et al. 2002). The 19S ATPase S6a in mammalian system was 
demonstrated to regulate Tat dependent transcription of HIV-1 genes (Lassot, Latreille et al. 
2007). Our lab has shown that 19S ATPases play an important role in promoting transcription 
initiation of MHCII and CIITA genes. The decreased expression of Sug1 results in decrease in 
the recruitment of CIITA to MHC II promoters  and a corresponding decrease in expression of 
MHCII genes (Bhat, Turner et al. 2008).  Sug1 regulates histone H3 acetylation at MHCII 
promoters through interaction with actylated histone H3. Knockdown of Sug1 ATPase with Sug1 
specific siRNA, results in decrease in histone acetylation at MHCII promoter and particularly at 
histone H3 lysine 18.  Sug1 recruits histone acetyltransferase CBP (CREB binding protein) to 
MHCII promoters and regulates histone modification at MHCII promoter regions (Koues, 
Dudley et al. 2008). Further Sug1 also regulates histone H3 lysine 4 trimethylation and Histone 
H3 arginine 17 dimethylation which are important activating modifications at both MHCII and 
CIITA promoters, indicating its role in transcription initiation of these immune genes (Koues, 
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Dudley et al. 2009, Koues, Dudley et al. 2009).  The 19S ATPase S6a plays was also shown to 
regulate histone H3 lysine 18 and histone H4 lysine 8 acetylation, which are activating 
modifications at CIITA promoters. Hence, these observations support that 19S ATPases of the 
26S proteasome play important roles in transcription initiation of cytokine inducible genes 
including MHCII and CIITA. 
 
In addition to their role in transcription initiation, we next wanted to determine if 
elongation was also regulated by 19S ATPases of the 26S proteasome. Initial observations 
indicate that inhibition of proteasome activity decreases recruitment of RNA pol II at yeast 
promoters was the first indication of the involvement of the proteasome in transcription 
elongation (Lipford, Smith et al. 2005). The 19S proteasomal ATPases have been shown to play 
roles in pol II dependent elongation in yeast.  These observations indicated that absence of the 
19S regulatory particle decreases transcription elongation  whereas absence of 20S proteolytic 
core increases transcription elongation (Ferdous, Gonzalez et al. 2001) (Ferdous, Kodadek et al. 
2002) (Gillette, Gonzalez et al. 2004) (Lipford, Smith et al. 2005). Thus, the two subunits of 
proteasome can function independently of each other and each is essential for transcription 
elongation and termination (Ferdous, Gonzalez et al. 2001) (Ferdous, Kodadek et al. 2002) 
(Gillette, Gonzalez et al. 2004) (Lipford, Smith et al. 2005). The 19S ATPase Sug1 was shown to 
interact with yeast elongation factor Cdc8 and regulate RNA pol II mediated elongation, while 
mutated Sug1 lead to defects in elongation (Ferdous, Gonzalez et al. 2001) (Kim, Bjorklund et 
al. 1994). Rpt6, has been shown to promote histone ubiquitination and methylation, which are 
important steps in elongation (Ezhkova and Tansey 2004) (Sun and Allis 2002). The 19S 
ATPase S6a in mammalian systems is recruited to coding regions of HIV-1 genes (Lassot, 
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Latreille et al. 2007). Thus, the components of 26S proteasome play roles in regulating RNA pol 
II mediated elongation. Observations in our lab further indicate recruitment of 19S ATPases to 
coding regions of CIITA, and mechanisms of involvement of these ATPases in transcription 
elongation are further described in Chapter 2 (Figure 1.7). 
 
1.8 Regulator of G-protein Signaling: 
RGS proteins are a large and diverse family of proteins which play canonical roles in 
regulating G-protein coupled receptor signaling. RGS proteins are composed of different sizes 
and variety of domains but share a conserved 120 amino acid domain called the RGS domain 
(Kimple, Bosch et al. 2011). This RGS domain has GTPase activating protein (GAP) activity at 
the Gα subunit of trimeric G proteins which promotes the hydrolysis of GTP into GDP, thus 
down-regulating GPCR mediated cellular signaling pathways (Popov, Yu et al. 1997) (Posner, 
Mukhopadhyay et al. 1999) (Tuteja 2009). However the hydrolysis of GTP to GDP is very slow 
but is accelerated by RGS proteins through their GAP activity (Hooks, Martemyanov et al. 
2008). The major role of RGS proteins is to regulate G-protein signaling through their GAP 
activity. There are more than 30 functional RGS genes in both mice and humans (Ross and 
Wilkie 2000) (Traynor 2010). Based on their domain structure and sequence homology the RGS 
protein family is divided into eight subfamilies (Wieland and Mittmann 2003) (Hollinger and 
Hepler 2002). 
Among members of the RGS protein family, RGS10 displays GAP activity against Gi 
family G-proteins (Hurst and Hooks 2009) (Figure 1.8). RGS10 associates with G-protein 
subunits Galphai3 and G alphaz and selectively increases GTP hydrolytic activity of G- alphai 
family and attenuates signaling pathways involving heterotrimeric G proteins (Hunt, Fields et al. 
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1996). RGS10 has been shown to inhibit GPCR mediated cell survival and proliferation 
signaling pathways in ovarian cancer cells (Hooks, Callihan et al. 2010) (Ali, Cacan et al. 2013) 
(Cacan, Ali et al. 2014). RGS10 expression is suppressed in ovarian cancer chemoresistance cells 
leading to enhanced sensitivity to G-protein coupled growth and to survival signals (Hooks, 
Martemyanov et al. 2008) (Hurst and Hooks 2009) (Hooks, Callihan et al. 2010). The decrease in 
RGS10 expression in chemoresistant ovarian cancer cells is due to two important epigenetic 
modulators: histone deacetylase 1 (HDAC1) and DNA methyl transferase 1 (DNMT1) 
association at RGS10 gene promoters (Cacan, Ali et al. 2014).  
RGS10 at the plasma membrane, through activation and deactivation of m2 muscuranic 
receptors, can promote GIRK channel activity (Burgon, Lee et al. 2001). RGS10 is 
predominantly expressed in bone osteoclast cells and regulates osteoclast differentiation. RGS10 
interacts with calcium/calmodulin and phosphotidyl inositol triphosphate (PIP3) in a [Ca2+] 
dependent manner and regulates PLCγ activation, [Ca2+] oscillations, and, through nuclear 
factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1) signaling pathways, 
promotes osteoclast differentiation (Yang and Li 2007).  
RGS10 protein is expressed in peripheral blood monocytes, splenic macrophages, and 
negatively regulates M1 macrophage activation by limiting NF-κB mediated cytokine production 
and primarily functions in anti-inflammatory fashion to regulate macrophage inflammatory stress 
responses (Lee, Chung et al. 2013). Some RGS proteins have functions independent of GAP 
activity, and RGS9-2 (Isoform 2 of RGS9) is abundantly expressed in the nuclei of forebrain 
neurons, and promotes transcriptional activity of a preprotachykinin A (PPT) neuronal gene 
construct promoter expressed in RGS9-expressing forebrain neurons. This indicates that nuclear 
RGS9-2 may either directly or indirectly alter transcription in vivo (Bouhamdan, Michelhaugh et 
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al. 2004). Recently it has been shown that RGS10 protein expressed in various neuronal cells in 
the brain region is also involved in suppressing neuroinflammation in a rat model of Parkinson’s 
disease (Lee, Chung et al. 2011). In our study we focus on whether RGS10 protein, which is 
abundantly expressed in the nucleus of microglial cells, when activated with inflammatory signal 
(lipopolysaccharide LPS) plays roles in transcription regulation of genes. Chapter 3 of this 
dissertation focuses on the mechanism by which RGS10 promotes its anti-inflammatory activity 
in chronically (LPS) activated microglial cells. 
1.9 Regulator of G-protein Signaling 10 and Role in Neuroinflammation 
RGS10 protein is expressed predominantly in the brain and particularly at high levels in 
the hippocampus, striatum, dorsal raphe, neurons and in microglia (Gold, Ni et al. 1997). RGS10 
is a 20kDa protein and is one of the smallest RGS proteins belonging to the R12 subfamily 
(Hunt, Fields et al. 1996) (Ross and Wilkie 2000). RGS10 is a selective GAP against Gi family 
G-proteins (Hollinger and Hepler 2002) and is highly expressed in the brain and immune tissues 
with specific enrichment in microglia (Waugh, Lou et al. 2005). Microglia are resident 
macrophages in the CNS and perform homeostasis functions in the CNS. Microglia are activated 
by nucleotides or nucleosides released from damaged neurons and through process extensions 
promote phagocytosis of apoptotic cells and mediate homeostasis conditions in the CNS 
(Domercq, Vazquez-Villoldo et al. 2013) (Raine 1994). Resting microglia have characteristic 
ramified morphology and are sensitive to changes in the brain microenvironment. They become 
activated in response to infection or brain injury and express Toll-like receptors (Neumann, 
Kotter et al. 2009) and help in the removal of pathogenic organisms and cell debris (Figure 1.9). 
Microglia upregulate expression of other cell surface receptors such as major histocompatibility 
complex and complement receptors (Liu and Hong 2003). 
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 Microglia undergo morphological changes from ramified cells to amoeboid microglia 
(Kreutzberg 1996). The activated microglial cells also secrete soluble factors such as 
neurotrophic factors beneficial for survival of neurons and proinflammatory cytokines include 
interleukin-1beta, tumor necrosis factor-alpha, free radicles such as nitric oxide or superoxide, 
which promote homeostasis in the CNS. However, excessive production of proinflammatory 
cytokines, (Boje and Arora 1992) (McGuire, Ling et al. 2001), can be deleterious to neurons 
(Figure 1.10). 
Cytokines are signaling molecules secreted by cells that help in cell to cell 
communication and play an important role in immune system’s defense against disease causing 
organisms. Cytokines promote the movement of immune cells towards sites of inflammation and 
infection and may act on cells that secrete them (autocrine), on nearby cells (paracrine) or on 
distant cells (endocrine). Proinflammatory cytokines such as IL-1, TNF-α, IL-6 are produced by 
monocytes activated macrophages such as microglial cells and are involved in upregulating 
inflammatory reaction. Studying the regulation of these proinflammatory cytokines will help in 
regulating neuroinflammation in the CNS.  
 
RGS10 expression in microglia serves to suppress microglial activation, proliferation, 
cytokine release, and inflammatory neurotoxicity (Lee, McCoy et al. 2008, Lee, Chung et al. 
2011). RGS10 inhibits activation of microglial NFκB, which may account for its 
immunosuppressive action (Lee, Chung et al. 2011). RGS10 contains sites for palmitoylation and 
for PKA-mediated phosphorylation which has been shown to mediate nuclear localization. 
Phosphorylation of RGS10 by cAMP-dependent Protein Kinase A (PKA) at Ser-168 induces 
translocation of RGS10 from plasma membrane and cytosol into the nucleus (Burgon, Lee et al. 
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2001). But the functional role of RGS10 in the nucleus is not clear. Neurodegenerative diseases 
such as multiple sclerosis, Alzheimer’s, Parkinson’s are mediated by neuroinflammation in the 
CNS, and a key player for maintaining homeostasis in the CNS are microglial cells (Raine 1994). 
Thus, studying the regulation of the RGS10 gene in microglial cells in chronic activation 
conditions will provide additional targets to combat neuroinflammation in the CNS, but it is 
unknown whether RGS10 regulates gene transcription in the nucleus. 
  
1.10 Basis for studying regulation of RGS10 in microglial cells: 
It has been recently shown that RGS10 null mice display increased microglial burden in 
the CNS and that inflammation induces degeneration of nigral dopaminergic neurons in a rat 
model of Parkinson’s disease (Lee, McCoy et al. 2008). RGS10 is also observed to be a negative 
regulator of NFκB dependent pro-inflammatory cytokine factor production in activated microglia 
(Lee, Chung et al. 2011). Thus, modulation of RGS10 activity in microglia provides 
neuroprotection both in vitro and in vivo against degeneration of neurons in a rat model of 
Parkinson’s disease. Our data shows that Lipopolysaccharide (LPS) activation of microglia leads 
to suppression of RGS10 expression. However, the mechanism by which RGS10 silencing in 
microglia remains unknown. Thus, studying the regulation of the RGS10 gene in microglial cells 
in chronic activation conditions will provide additional targets to combat neuroinflammation in 
the CNS. 
 
Among autoimmune diseases, Multiple Sclerosis is mediated by neuroinflammation in 
the CNS and key players for maintaining homeostasis in the CNS are microglial cells. Thus, 
studying the regulation of the RGS10 gene in microglial cells in chronic activation conditions 
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will provide additional targets to combat neuroinflammation in MS disease. The focus of Chapter 
3 in this dissertation will be to elucidate potential mechanisms by which transcription can be 
used as a modulator of adaptive immune response and neuroinflammation by regulating 
expression RGS10 genes that mediate homeostasis condition in the CNS. 
1.11 Summary 
Tight regulation of gene expression is for normal cellular function. One way of regulating 
gene expression is through transcription, which itself if mediated by hundreds of proteins and 
enzymes. Dysregulated gene expression is the cause of a majority of human diseases. Therefore 
the molecular and functional characterization of transcription factors and enzymes provides 
application to the treatment of disease. One disease family often regulated at the level of 
transcription is autoimmune disease. Autoimmune diseases are regulated by autoreactive 
immune responses where, instead of antigen specific immune responses that help fight 
infections, the immune response is targeted against self tissues. Our work focuses on the critical 
immune regulators MHC II and CIITA, which play crucial role in initiating adaptive immune 
responses and are both regulated at the level of transcription. It is of utmost importance to 
understand how CIITA transcription is regulated which in turn drives MHC class II cell surface 
expression in order to in turn impact autoimmune disease. 
The 26S proteasome, a component of the non-lysosomal protein degradation machinery 
in the cell, is also essential for gene expression. The 26S mediates transcription initiation by 
promoting localization of transcription factors to promoter region of genes, exchange of 
transcription factors, stabilization of transcriptional complexes, and finally, their proteolytic 
degradation leading to transcription termination (Collins and Tansey 2006). Non-proteolytic 
roles for the 26S involves ubiquitin-dependent histone modification, recruitment of elongation 
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factors, and facilitates transcription elongation (Kwak, Workman et al. 2011) (Bhat and Greer 
2011) (Collins and Tansey 2006). Together these data indicate multiple roles for the 
ubiquitin/proteasome pathway in regulating mammalian gene transcription. 
The 19S regulatory particle and 20S proteolytic core together constitute the 26S 
proteasome and each component has distinct roles in transcription regulation (Ferdous, Kodadek 
et al. 2002) (Gonzalez, Delahodde et al. 2002). The 19S ATPases of the regulatory particle 
associate with actively transcribing genes in yeast (Gonzalez, Delahodde et al. 2002) and also 
regulates elongation (Ferdous, Gonzalez et al. 2001) (Ferdous, Kodadek et al. 2002). The role of 
19S proteasomal subunits in transcription elongation of mammalian  immune gene transcription 
remains unclear. 
In the light of the novel non-proteolytic roles of 19S ATPases of the 26S proteasome in 
transcription regulation of yeast genes, it is probable that these subunits have roles in inducible 
CIITA gene transcription. As CIITA is the master regulator of MHCII genes, CIITA expression 
correlates with that of MHCII. Therefore, studying the roles played by subunits of 19S regulatory 
particle of the UPS in regulating CIITA transcription will not only aid in the development of 
novel therapeutic targets to manipulate MHC class II gene expression in diseased conditions 
such as autoimmune disorders but will also further our knowledge of the role of 19S proteasomal 
subunits in mammalian immune gene transcription.  
To better understand transcriptional regulation of CIITA, we investigated novel roles 
played by 19S ATPases of the 26S proteasome in regulating transcription elongation of 
CIITApIV. Here, we define novel, non-proteolytic, roles for each of the three 19S heterodimers, 
represented by the 19S ATPases Sug1, S7, and S6a in transcription elongation of CIITApIV 
24 
genes. These 19S ATPases are recruited to induced CIITApIV promoters and also associate with 
CIITA coding regions. Additionally, these ATPases interact with elongation factor PTEFb 
complex members CDK9 and Hexim-1 and with Ser5 phosphorylated RNA Pol II. Both the 
generation of transcripts from CIITApIV and efficient recruitment of RNA Pol II, TATA binding 
protein (TBP) to CIITApIV are negatively impacted by siRNA mediated knockdown of the 19S 
ATPases. In chapter 2 we demonstrate novel ways of regulating transcription of CIITApIV, 
where 19S ATPases Sug1, S7 and S6a play an important role in transcription initiation and 
elongation. 
There is evidence of the role of Regulator of G-protein Signaling (RGS) proteins, 
particularly RGS-10, in regulating neuroinflammation in the CNS observed in several 
neurodegenerative diseases; however; the molecular mechanisms remain unknown. RGS proteins 
have the ability to regulate G-protein Coupled Receptor Signaling (GPCR) signaling by acting as 
GAP but it is not known how they can regulate neuroinflammation in the CNS. A recent study 
reported that lack of RGS10 in mice resulted in increased microglial burden in the CNS and 
further induction of chronic systemic inflammation promoted degeneration of dopaminergic 
neurons in the brain region (Lee, McCoy et al. 2008). The immune cells in the CNS such as 
microglial cells constantly survey the microenvironment in the brain region and promotes 
homoeostasis, however, excessive activation of these cells leads to production of 
proinflammatory cytokines, free radicals, reactive oxygen species and promote 
neuroinflammation. Microglial cells were found to have abundant expression of RGS10 protein 
in nucleus, cytoplasm but mechanistic role of RGS10 in suppressing neuroinflammation remains 
unclear. Indirect evidence indicates that RGS10 modulates NF-κB signaling and neuroprotects 
dopaminergic neurons, but in microglial cells lacking RGS10 expression promotes pro-
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inflammatory conditions (Lee, Chung et al. 2011). These studies suggest that RGS10 is 
abundantly present in microglial cells and it has anti-inflammatory activity. In chapter 3, we 
investigate the mechanistic role of how RGS10 might be promoting its anti-inflammatory 
activity in BV2 microglial cells. Understanding the regulatory role of RGS10 in microglial cells 
is an important step towards developing better therapeutic targets for treating neuroinflammation 
in the CNS. 
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Figure 1.1 MHCII promoter region 
MHCII promoter region consists of conserved cis-acting sequence elements X1, X2 and Y 
boxes. The X1 box is bound by transcription factor regulatory factor X (RFX (RFX5,RFX-AP, 
RFX-ANK), X2 box is bound by cAMP response element binding protein (CREB) and Y box is 
bound by nuclear factor Y (NFY). All these factors form the enhanceosome complex which is 
necessary but is alone not sufficient to initiate MHCII synthesis. It requires recruitment of class 
II transactivator (CIITA) which then binds to enhanceosome complex and recruits RNA 
polymerase II and histone modifying enzymes such as histone acetyl transferases, histone methyl 
transferases for making MHCII promoter accessible for transcription (Benoist and Mathis 1990) 
(Ting and Trowsdale 2002). 
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Figure 1.2 MHCII molecules are critical for activating the adaptive immune response    
MHC II molecules are cell surface glycoproteins and are present on all antigen presenting cells 
(APC). Additionally, MHC II can be induced on all other cells types through the stimulation by 
the cytokine interferon gamma (IFN-γ). APC’s have the ability to recognize, process and present 
the antigens on MHCII molecules to CD4+ T lymphocytes which result in T cell activation. 
Activated CD4+ T cells can activate B lymphocytes to produce specific antibody producing 
plasma cells and elicit an adaptive immune response. Activated CD4+ T cells also activate 
cytotoxic CD8+ T lymphocytes, to direct cell-mediated killing (Parham 2009; Owen, Punt et al. 
2013).  
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Figure 1.3 The promoter region of CIITA 
(Top) Transcription of CIITA is driven by one of the four promoters in cell-type and cytokine-
specific manner. CIITA isoform I is expressed from pI in dendritic cells and macrophages, 
Isoform II is not conserved and is thought to be inactive, Isoform III is expressed in B- cells and 
is up-regulated in response to IFN-gamma. CIITA promoter pIV is responsible for IFN- γ 
inducible expression in nucleated cells (Muhlethaler-Mottet, Otten et al. 1997) (Piskurich, 
Gilbert et al. 2006). 
 
(Bottom) The promoter region of CIITApIV isoform has three conserved sequences: the GAS, 
ISRE and E-box. STAT-1 binds to the GAS box, then IRF-1 and IRF-2 are recruited to ISRE, 
and USF-1 is a constitutively expressed transcription factor binds to E-box. Recruitment of all 
these transcription factors is synchronized with the recruitment of the histone modifying 
enzymes including HATs, HMTs and HDACs that regulate the accessibility of the chromatin and 
the further recruitment of the basal transcription machinery that will initiate transcription of 
CIITApIV genes (Muhlethaler-Mottet, Di Berardino et al. 1998) (Wright and Ting 2006). 
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Figure 1.4 MHCII is IFN-γ inducible: Activation of JAK-STAT signal transduction 
pathway 
IFN-γ binds to its receptor and initiates the kinase function of JAK, which autophosphorylates 
itself. The STAT protein then binds to phosphorylated receptor. Once phosphorylated STAT-1 
translocates to nucleus, where STAT-1 binds to CIITA isoform IV. IRF-1 (Interferon response 
factor-1) binds to CIITApIV together with ubiquitously expressed USF-1 and initiate expression 
of CIITA. CIITA protein, the master regulator of MHC II genes then binds ubiquitously 
expressed components of the enhanceosome complex and initiate expression of MHC class II 
genes (Piskurich, France et al. 1993). 
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Figure 1.5 The 26S proteasome 
The 26S proteasome is composed of a 20S proteolytic core capped on one or both ends by the 
19S regulatory particle. The 20S core is a hollow cylindrical structure composed of two 
heptameric rings of α-subunits and two heptameric rings of β-subunits. The 20S core is capped 
on one or both sides by a 19S regulatory particle to form the active 26S proteasome. The 19S 
regulatory particle is composed of a base and a lid component. The lid component consists of 
nine non-ATPase subunits and the base is composed of six ATPases (S7, S4, S6a, S10b, Sug1 
and S6b) and four non-ATPases (S1, S2, S5a and S5b) ((Beck, Unverdorben et al. 2012)Beck et 
al. 2012; (da Fonseca, He et al. 2012)da Fonseca et al. 2012). Polyubiquitinated proteins are 
recognized, deubiquitinated, and unfolded by the 19S regulatory particle and the unfolded 
proteins are translocated to the 20S core where proteins are degraded into small peptides (He, Qi 
et al. 1998). 
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Figure 1.6 The 19S ATPase heterodimers 
The 19S Base consists of six ATPases S4, S6a, S6b, S7, Sug1, Sug10b all of which belong to the 
AAA (ATPases Associated with diverse cellular Activity) superfamily. In vitro binding studies 
show the formation of dimers S4 binds S7; S6b binds Sug1; S6a binds S10b (Richmond, Gorbea 
et al. 1997).  
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Figure 1.7 Dynamics of Transcription Elongation of CIITApIV gene 
Transcription elongation is regulated by interaction with specific transcription factors. PTEF-b is 
in an inactive complex with Hexim and 7SK RNA. Once stimulated with IFN-γ Hexim and 7SK 
RNA dissociates from the complex allowing PTEFb to transform into an active for. Active 
PTEFb complex consists of CyclinT1 and CDK9 which is then recruited to CIITA. Then a series 
of phosphorylation events are mediated by CDK9 subunit of PTEF-b. CDK9 phosphorylates 
Ser2 of RNA pol II CTD, NTEF and DSIF to release the inhibition on RNA pol II. NTEF and 
DSIF after phosphorylation are released from the paused RNA pol II complex and thus helps in 
the transition from initiation to elongation complex (Sims, Belotserkovskaya et al. 2004) 
(Barboric, Kohoutek et al. 2005).    
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Figure 1.8 RGS10 protein accelerates the GTP-ase activity of heterotrimeric G-protein Gα-
subunit. 
Agonist binding to GPCR activates G-proteins, which mediate downstream signaling pathways. 
In the inactive state, the α-subunit is bound to GDP. Upon LPS activation, conformational 
changes in the receptor induce the Gα-subunit to release GDP and bind GTP. The binding of 
GTP causes dissociation of the α-subunit and the βγ dimer, allowing them to interact with 
effector molecules and promote signaling cascades associated with cellular survival, growth, 
migration and invasion. G-protein signaling is deactivated when the α-subunit hydrolyzes GTP to 
GDP and reassociates with the βγ dimer. RGS10 protein functions to accelerate the GTPase 
activity of the α-subunit, thereby inhibiting downstream activity 
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Figure 1.9 Protective function of Microglial cells 
The release of nucleotides/nucleosides from injured neurons, astrocytes or microglial cells 
promote alterations in microglia. Microglial processes have constitutive motility which is 
dependent on ATP signaling. Microglial cells are rapidly recruited to sites of CNS tissue damage 
by P2Y12 and A3 receptor activation. Activated microglia now show changes such as altered 
expression of cell surface markers and inflammatory genes, process retraction and attain 
ameboid morphology followed by cell body migration and increasing phagocytic ability. The 
changes in microglial functions are associated with changes in purinergic receptors  and they 
respond to ATP. Process retraction is due to upregulation of A2A and downregulation of P2Y12 
receptors and migration is mediated by A1 and P2X4 receptors and proliferation by P2X7 
receptors. Phagocytosis is mediated by P2Y6 receptors, which are activated by UDP from dying 
cells (Domercq, Vazquez-Villoldo et al. 2013).  
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Figure 1.10 Chronic microglial activation is neurotoxic 
Microglia can become overactivated and cause neurotoxicity by two ways: First, microglia can 
initiate neuron damage by recognizing stimuli such as lipopolysaccharide (LPS) become 
activated produce neurotoxic factors such as IL-1beta, TNF-alpha, nitric oxide, superoxide, 
prostaglandin E2. Second, microglia can become overactivated in response to neuronal damage 
(reactive microgliosis) which is further toxic to the surrounding neurons, resulting in an another 
cycle of neuron death. Reactive microgliosis is the mechanism for progressive neuron damage 
across numerous neurodegenerative diseases (Block, Zecca et al. 2007). 
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2 CHAPTER II: Nonproteolytic roles of 19S ATPases in transcription of 
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2.1 Abstract 
Accumulating evidence shows the 26S proteasome is involved in the regulation of gene 
expression. We and others have demonstrated that proteasome components bind to sites of gene 
transcription, regulate covalent modifications to histones, and are involved in the assembly of 
activator complexes in mammalian cells. The mechanisms by which the proteasome influences 
transcription remain unclear, although prior observations suggest both proteolytic and non-
proteolytic activities. Here, we define novel, non-proteolytic, roles for each of the three 19S 
heterodimers, represented by the 19S ATPases Sug1, S7, and S6a, in mammalian gene 
expression using the inflammatory gene CIITApIV. These 19S ATPases are recruited to induced 
CIITApIV promoters and also associate with CIITA coding regions. Additionally, these ATPases 
interact with elongation factor PTEFb complex members CDK9 and Hexim-1 and with Ser5 
phosphorylated RNA Pol II. Both the generation of transcripts from CIITApIV and efficient 
recruitment of RNA Pol II to CIITApIV are negatively impacted by siRNA mediated knockdown 
of these 19S ATPases. Together, these results define novel roles for 19S ATPases in mammalian 
gene expression and indicate roles for these ATPases in promoting transcription processes. 
 
2.2 Introduction 
Each stage in gene expression involves many proteins that must assemble and 
disassemble at the right time and place and in the correct order and abundance. While the 
mechanisms by which cells regulate the location, timing, and amount of proteins involved in 
gene expression remain unclear, recent observations have linked the 26S proteasome, an 
essential regulator of protein degradation, to several stages of gene expression. The 26S 
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proteasome in mammalian cells is a 2.5 MDa multi-protein complex comprised of a 19S 
regulatory particle (RP) and a 20S proteolytic core (Baumeister, Walz et al. 1998) each of which 
exists independently in both the nucleus and cytoplasm (Peters, Franke et al. 1994). The 19S RP 
is further divided into two parts: a lid and a base. The lid is composed of eight non-ATPase 
subunits that are required for protein degradation (Coux, Tanaka et al. 1996, Baumeister, Walz et 
al. 1998, Gorbea, Taillandier et al. 1999). The base of the 19S contains six ATPases, 
representing three heterodimeric pairs (Sug1 and S6b, S7 and S4, and S6a and S10b), which 
belong to the ATPases associated with a variety of cellular activities (AAA) family. The base 
also contains four non-ATPase subunits: S2, S1, S5a, and S5b (Gorbea, Taillandier et al. 1999, 
Adams 2003, Bhat, Turner et al. 2008, Beck, Unverdorben et al. 2012, da Fonseca, He et al. 
2012, Lasker, Forster et al. 2012).  
 
The 20S catalytic core of the proteasome is a 700 kDa cylinder that consists of four 
stacked rings, with each ring containing seven α and β subunits (Coux, Tanaka et al. 1996, 
Gorbea, Taillandier et al. 1999). The base ATPases contain a C-terminal hydrophobic tyrosine X 
motif that docks into the pockets of the α rings of the 20S (Smith, Chang et al. 2007). In the 
presence of ATP, the 19S regulatory particle associates with the 20S catalytic core on both sides 
to form the 26S proteasome, allowing for the recognition of polyubiquitinated substrates marked 
for degradation (Coux, Tanaka et al. 1996, Gonzalez, Delahodde et al. 2002). The 19S regulatory 
particle recognizes the ubiquitin chains on targeted proteins, cleaves the chains, unfolds the 
protein, and directs the unfolded protein to the 20S core for degradation (Coux, Tanaka et al. 
1996, Strickland, Hakala et al. 2000) (Figure 2.1). Accumulating evidence suggests the 19S 
proteasome not only recognizes ubiquitinated substrates for proteolysis, but also is linked to gene 
39 
transcription in numerous different contexts, including mRNA elongation in yeast and 
mammalian cells (Ferdous, Kodadek et al. 2002, Muratani and Tansey 2003, Chaves, Baskerville 
et al. 2010). 
 
We detail here non-proteolytic involvement of the 19S ATPases in regulating gene 
expression from an immunologically important mammalian promoter, the Class II Transactivator 
(CIITA) which is the master regulator of Major Histocompatibility class II (MHC II) genes (Ting 
and Trowsdale 2002). CIITA is expressed constitutively on antigen presenting cells, and is 
inducibly expressed on all nucleated cells upon stimulation with the inflammatory cytokine 
interferon gamma (IFN-γ) (Kaufman, Auffray et al. 1984, Boss 1997). CIITA-driven MHC II 
molecules play critical roles in activating adaptive immune responses by binding and presenting 
exogenously derived antigenic peptides to CD4+ T lymphocytes (Ting and Trowsdale 2002). 
MHC II deficiencies lead to the development of Bare Lymphocyte Syndrome (BLS) (Reith and 
Mach 2001) and Severe Combined Immune Deficiency (SCID) (Swanberg, Lidman et al. 2005) 
while overexpression of MHC II is associated with the development of autoimmune disease 
(Trowsdale 2011). The presentation of tumor cell antigens by MHC II molecules is critical in the 
detection of newly formed tumors (Guy, Krajewski et al. 1986, Garrido and Ruiz-Cabello 1991). 
Because MHC II molecules play these critical roles in the activation of adaptive immune 
responses, and since deregulation of MHC II has such dire consequences, MHC II expression is 
tightly regulated, primarily at the level of transcription by CIITA (Benoist and Mathis 1990).  
 
Expression of CIITA is regulated in a cell specific manner by four distinct promoters: pI, 
pII, pIII, and pIV (Boss and Jensen 2003). CIITA expression is induced at pIV when IFN-γ binds 
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to the INF-γ surface receptor (Morris, Beresford et al. 2002, Pattenden, Klose et al. 2002, 
Piskurich, Gilbert et al. 2006). In addition to promoting the binding of transcription factors to 
pIV, IFN-γ also induces acetylation of histones, which loosens the chromatin structure and 
increases the accessibility of CIITApIV (Sterner and Berger 2000, Wright and Ting 2006). 
Following IFN-γ stimulation, a large, ubiquitously expressed multi-protein enhanceosome 
complex, consisting of Regulatory Factor X (RFX), Nuclear Factor Y (NF-Y), and cAMP 
Response Element Binding (CREB) (Masternak, Muhlethaler-Mottet et al. 2000) binds the MHC 
II proximal promoter and recruits newly expressed CIITA (Reith and Mach 2001, Ting and 
Trowsdale 2002). Once bound to the MHC II enhanceosome, CIITA stabilizes the enhanceosome 
complex and recruits basal transcription components and RNA Polymerase II (Pol II) (Mach, 
Steimle et al. 1996, Masternak, Barras et al. 1998, Kanazawa, Okamoto et al. 2000, Boss and 
Jensen 2003).  
 
We recently identified novel roles of the 19S ATPases in regulating acetylation and 
methylation of histones H3 and H4 at CIITApIV and the MHC II promoter (Koues, Dudley et al. 
2008, Koues, Dudley et al. 2009, Koues, Mehta et al. 2010, Truax, Koues et al. 2010). Following 
IFN-γ stimulation, the 19S ATPases bind to the MHC II and CIITApIV promoters. Diminished 
expression of 19S ATPases inhibits MHC II and CIITApIV promoter histone acetylation and co-
factor binding (Koues, Dudley et al. 2008, Koues, Dudley et al. 2009), enhances suppressive 
histone H3 lysine 27 trimethylation (Koues, Dudley et al. 2009), and results in repression of 
transcription (Koues, Mehta et al. 2010). Following chromatin activation by histone modifying 
enzymes, activator and activator complexes must be recruited to the promoter regions of target 
genes. To this end, in the absence of 19S ATPases, transcription factor recruitment to CIITApIV 
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and to the MHC II promoter is also dramatically reduced (Bhat, Turner et al. 2008, Koues, 
Dudley et al. 2008, Koues, Dudley et al. 2009, Truax, Koues et al. 2010).  
 
Despite growing understanding of the importance of the proteasome in mammalian gene 
expression, roles for the proteasome in the various stages of transcription remain unclear. We 
demonstrate here the 19S ATPases have critical, non-proteolytic roles in the regulation of early 
and intermediate stages of transcription at CIITApIV. The 19S ATPases associate with the 
CIITApIV proximal promoter, participate in RNA Pol II recruitment, and move into coding 
regions where they may regulate elongation by their interaction with both inactive and active 
forms of elongation factor PTEF-b. Depletion of 19S ATPases Sug1, S7, or S6a by siRNA 
abrogates CIITApIV transcription, with increasing impact on longer transcripts. The 19S 
ATPases also associate with Ser5p-RNA pol II and their knockdown negatively impacts the 
recruitment of RNA pol II to CIITA pIV. Together, our studies suggest the 19S ATPases are 
intimately involved in transcription of the critical adaptive immune gene CIITA. 
 
2.3 Materials and Methods 
2.3.1 Cell Culture 
HeLa cells (human epithelial) from ATCC (Manassas, VA) were cultured using high-
glucose Dulbecco modified Eagle (DMEM) medium (Mediatech Inc., Herndon, VA) 
supplemented with 10% fetal bovine serum, 5mM penicillin-streptomycin, and 5mM L-
glutamine. The cells were maintained at 37˚C with 5% CO2. 
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2.3.2 Antibodies 
Sug1 and S7 antibodies were obtained from Novus Biologicals (Littleton, CO). S6a 
antibody was obtained from Biomol International LP (Plymouth meeting, PA). Histone H3, and 
mouse IgG control antibodies were obtained from Millipore (Lake Placid, NY). RNA Pol II, 
Ser5p RNA Pol II and Ser2p RNA Pol II antibodies were obtained from Abcam (Cambridge, 
MA), horseradish peroxidase (HRP) conjugated mouse antibody was obtained from Promega 
(Madison, WI), and (HRP)-conjugated rabbit antibody was obtained from Pierce (Rockland, IL). 
Anti-Myc and Flag-HRP conjugated antibodies and Anti-mouse HA antibody were obtained 
from Sigma (St. Louis, MO). 
 
2.3.3 Plasmids 
pBluescript (pBS) S7 and S6a plasmids were generous gifts from Dr. Martin Rochesteiner 
(Richmond, Gorbea et al. 1997, Rabl, Smith et al. 2008). These two genes were subcloned into 
Myc tagged pCMV-3 using the EcoR1 restriction site. Myc-Sug1 was kindly provided by Dr. A. 
Wani and has been previously described (Koues, Dudley et al. 2008). Flag-Hexim1 plasmid was 
kindly provided by the Price Lab (Li, Price et al. 2005), and HA-CDK9 was kindly provided by 
the Zhou Lab (Zhou, Chen et al. 1998). 
 
2.3.4 siRNA constructs and transfections 
Short interfering RNA (siRNA) duplexes were used for transient knockdown of 19S 
ATPases Sug1, S7, and S6a. The siRNA sequences of Sug1 and S7 siRNA used were 5’-
AAGGTACATCCTGAAGGTAAA-3’ and 5’-AACTGCGAGAAGTAGTTGAAA-3’ 
respectively (Qiagen, Valencia, CA) (Bhat, Turner et al. 2008, Koues, Dudley et al. 2008). The 
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S6a siRNA sequence was a predesigned siRNA directed against PSMC3 (Truax, Koues et al. 
2010). A scrambled siRNA sequence was used as a negative control (Qiagen, Valencia, CA). 
HeLa cells were transfected with scrambled sequence control siRNA or with ATPase-specific 
siRNA using HiPerfect transfection reagent (Qiagen) according to the manufacturer’s 
instructions and were then treated with IFN-γ (500 U/ml) as indicated. Cells were lysed in NP-40 
lysis buffer (1M Tris pH 8.0, 1M KCl, 10% NP-40, 0.5M EDTA, 5M NaCl, 1M DTT, dH2O), 
supplemented with complete EDTA-free protease inhibitors (Roche, Florence, SC), and 
knockdown specificity and efficiency was assessed by Western blotting using anti-Sug1, S7, or 
S6a primary antibodies at 1:2000 concentration overnight at 4˚C. Mouse-HRP conjugated 
secondary antibody was used at concentration of 1:20,000 for 1h at room temperature. 
 
2.3.5 RNA expression 
HeLa cells were plated at a density of 8 x 105 in 10 cm tissue culture plates and 24h later 
were transfected with control or ATPase specific siRNA. Forty-eight hours following siRNA 
transfection, cells were stimulated with IFN-γ (500 U/ml) for 18h. Six hours prior to harvest, 
cells were treated with 10µM of the proteasome inhibitor MG132 (EMD Biosciences) or with 
10µM of the proteasome inhibitor Lactacystin from Biomol International LP (Plymouth meeting, 
PA). Cells were harvested, washed with cold PBS, centrifuged at 3000 rpm at 4˚C for 5 minutes, 
and total RNA was prepared with 1ml of Trizol reagent (Invitrogen, Carlsbad, CA) in accordance 
with the manufacturer’s instructions. The Omniscript Reverse Transcription Kit (Qiagen) was 
used to generate cDNA from extracted RNA. Gene specific antisense primers (Sigma, Saint 
Louis, MO) were used for reverse transcription. PCR conditions for all Q-PCR reactions 
included an initial 10 minute incubation step at 65˚C followed by a 60 minute incubation step at 
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37˚C in accordance with the manufacturer’s instructions (Qiagen). The cDNA for CIITA mRNA 
short (exon IV), CIITA mRNA long (exon VII), and for GAPDH mRNA was amplified using the 
following reverse primers: 5’-GCT CCA GGT AGC CAC CTT CT-3’; 5’-AGC AGT CGC TCA 
CTG GTC TCA-3’; 5’-TAG ACG GCA GGT CAG GTC CA-3’.  Real-time PCR reactions were 
carried out on an ABI Prism 7900 (Applied Biosystems, Foster City, CA). Probes for CIITA 
promoter IV (CIITApIV) and CIITA exon IV and exon VII were 5’ labeled with 6-
carboxyfluorescein (FAM) reporter dye and 3’ with N,N,N,N-tetramethyl-6-carboxyrhodamine 
(TAMRA) quencher dye. Isolated DNA was analyzed by real-time PCR using primers and 
probes spanning: 
 
•CIITApIV mRNA short (exon IV)–sense sequence 5’-GGG AGA GGC CAC CAG 
CAG-3’, antisense sequence 5’-GCT CCA GGT AGC CAC CTT CT-3’, probe sequence 5’-
FAM-CTG TGA GCT GCC GCT GTT CCC-3’TAM.  
•CIITApIV mRNA long (exonVII)–sense sequence 5’-AAC ACA GCC CAC TTC CTC 
ACA-3’, antisense sequence, 5’-AGC AGT CGC TCA CTG GTC TCA-3’, probe sequence 
5’FAM-ACT GTG GTG ACT GGC AG-3’TAM)  
•GAPDH mRNA – sense sequence 5’-GGA AGC TCA CTG GCA TGG C-3’, antisense 
sequence 5’-TAG ACG GCA GGT CAG GTC CA-3’, probe sequence 5’-FAM-CCC CAC TGC 
CAA CGT GTC AGT G-3’TAM)   
 
 Values from real-time PCR reactions were calculated and graphed based on 
standard curves generated and were normalized to GAPDH message levels. Samples were run in 
triplicate reactions and were analyzed using the SDS 2.0 program (Applied Biosystems, Foster 
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City, CA). Graphed values represent the percentage difference in the mRNA molecules with 
respect to ATPase specific siRNA treated and non-treated cells. The highest value is considered 
100% and other values were graphed in terms of percentage.  
 
2.3.6 RNA expression with ATPase knockdowns 
HeLa cells were plated at a density of 8 x 105 in 10 cm tissue culture plates and 24h later 
were transfected with Sug1, S7, or S6a siRNA. Forty-eight hours following siRNA transfection, 
cells were stimulated with IFN-γ (500 U/ml) for 18h. Six hours before harvest, cells were treated 
with 10µM MG132 or with 10µM Lactacystin proteasome inhibitor. Cells were harvested and 
10% of the cells were lysed with 1% Nonidet P-40 buffer with protease inhibitors and were 
analyzed by Western blotting for ATPase knockdown efficiency. The remaining fraction of cell 
volume was subjected to RNA extraction as above. 
 
2.3.7 Heat Shock Assay with S6a ATPase knockdown 
HeLa cells were plated at a density of 65,000 cells in a 48 well plate, after 24 hrs the cells 
were transfected with the indicated plasmids Heat Shock Element promoter tagged with 
Luciferase (Reddy, Shenoy et al.) and with either control siRNA or S6a siRNA using Attractene 
(Cignal heat shock reporter assay kit, Qiagen, Valencia, CA) according to manufacturer’s 
instructions. Cells were treated with proteasome inhibitor (MG132) 4 hrs prior to harvest. After 
48 hrs, the cells were harvested, washed with cold PBS, and lysed using 1x cell lysis reagent 
(Promega, Madison, WI). The lysed cell suspension was centrifuged for 2 minutes at 12,000 rpm 
(Thermo electron 851, Thermo INC, Needham Heights, MA) at 4 ̊ C and a Luciferase assay 
(Promega) was performed according to the manufacturer’s instructions. Ten percent of the cell 
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lysates were normalized for protein concentration by Bradford assay (Bio-Rad), separated by 
SDS-PAGE, transferred to nitrocellulose and immunoblotted with monoclonal antibody to S6a 
and secondary goat anti-mouse horseradish peroxidase conjugated antibody. The negative 
control is a mixture of non-inducible reporter construct and constitutively expressing Renilla 
luciferase construct provided in the kit. Positive control is an inducible transcription factor-
responsive construct expressing firefly luciferase, and a constitutively expressing Renilla 
luciferase construct; both are provided in the kit.  
 
2.3.8 Co-immunoprecipitation 
HeLa cells were plated at a density of 8 x 105 in 10 cm tissue culture plates and 
transfected with 5µg of Myc-Sug1, Myc-S7, or Myc-S6a and 5µg of pcDNA, HA-CDK9, or 
Flag-Hexim plasmids using Fugene 6 (Roche, Indianapolis, IN) according to manufacturer’s 
instruction. After 24 h, cells were harvested and lysed using RIPA lysis buffer (1M Tris pH 8.0, 
5M NaCl, 10% NP-40, 5% DOC, 10% SDS, 1M DTT, dH2O) supplemented with complete 
EDTA-free protease inhibitor (Roche, Indianapolis, IN). Cell lysates were centrifuged, 
normalized for protein concentration, and pre-cleared with 50µl mouse IgG (Sigma, Saint Louis, 
MO) and were immunoprecipitated overnight with 10µg antibody against Sug1, S7, or S6a. 
Negative control samples were immunoprecipitated overnight with 10µg of mouse IgG. Immune 
complexes were isolated with Myc beads (for 19S ATPases) (Sigma), Flag beads (for Flag-
Hexim 1) (Sigma) or HA beads (for HA-CDK9) (Sigma) on a rotator at 4˚C and complexes were 
denatured with Leammli buffer (Bio-Rad), boiled, and separated by SDS-PAGE gel 
electrophoresis. Gels were transferred to nitrocellulose and co-immunoprecipitated complexes 
were detected by immunoblotting using mouse anti-Myc-HRP to detect Myc-tagged ATPases, 
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mouse anti-Flag-HRP to detect Flag-Hexim 1, and mouse anti-HA antibody to detect HA-CDK9.  
HRP conjugates were detected with the HyGlo Chemiluminiscent reagent kit (Denville). Equal 
loading was determined in non-immunoprecipitated lysates by immunoblotting of total protein. 
 
For endogenous co-immunoprecipitation experiments, 7 x 106  HeLa cells were lysed in 
NP-40 lysis buffer with protease inhibitors for 30 minutes on ice. Lysates were centrifuged, 
normalized for protein concentration, precleared with 50 µl mouse IgG (Sigma-Aldrich) and 
were immunoprecipitated with 5 µg of antibody against Sug1, S7, or S6a respectively. Positive 
control samples were immunoprecipitated with 5 µg of Hexim, CDK9 or Ser5p RNA pol II 
antibody and negative control samples were immunoprecipitated with 5 µg of mouse IgG. 
Isolated immune complexes were denatured with Leammli buffer, boiled and separated by SDS-
PAGE gel electrophoresis. Gels were transferred to nitrocellulose and were individually 
immunoblotted for endogenous Hexim, CDK9 or Ser5p RNA pol II. Equal loading was 
determined in non-immunoprecipitated lysates by immunoblot of total protein. 
 
2.3.9 Chromatin Immunoprecipitation  
HeLa cells were plated at a density of 2.5 x 106 in 15 cm-tissue culture plates and were 
treated with IFN-γ (500 U/ml) for 0.5, 2, 3, 4, or 18hrs. Following IFN-γ stimulation, cells were 
crosslinked with 1% formaldehyde for 8 minutes at room temperature; crosslinking was stopped 
by the addition of 0.125M glycine for 5 minutes at room temperature. Cell nuclei were isolated 
and concentrated by lysing in cell lysis buffer (5mM PIPES pH 8, 85mM KCl, 1% igepal) and 
protease inhibitors for 15 minutes on ice.  The cell lysate was centrifuged at 2100 rpm for 5 
minutes at 4˚C.  The supernatant was discarded and the pellet was resuspended in SDS lysis 
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buffer (1% SDS, 10mM EDTA, 50mM Tris pH 8.0, dH2O) and protease inhibitors for 25 
minutes on ice followed by flash freezing in liquid nitrogen. Lysed nuclei were sonicated using a 
Bioruptor water bath sonicator for 30 sec “On” and 30 sec “Off” 3 times to generate an average 
of 1000 bp of sheared DNA. The sonicated lysates were pre-cleared with salmon-sperm coated 
agarose beads (Upstate) and lysates were divided equally. One half of the lysate was 
immunoprecipitated with 5µg of antibody to Sug1, S7, S6a, or RNA Pol II overnight at 4˚C. The 
other half of the lysate was immunoprecipitated with control antibody. Immunoprecipitated 
proteins were isolated during 2h incubation with 60 µl of salmon-sperm coated agarose beads. 
Immunoprecipitated samples were washed for 3 minutes at 4˚C with the following buffers: low 
salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.0, 150mM NaCl, 
dH2O), high salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.0, 500 mM 
NaCl, dH2O), LiCl buffer (0.25M LiCl, 1% NP40, 1% DOC, 1mM EDTA, 10mM Tris pH 8.0, 
dH2O) and 1X TE buffer; DNA was then eluted with SDS elution buffer (1% SDS, 0.1M 
NaHCO3, dH2O). After DNA elution, crosslinks were reversed overnight with 5M NaCl at 65˚C 
followed by treatment with proteinase K for 1 hr at 45˚C and immunoprecipitated DNA was 
isolated using a phenol:chloroform:isopropanol mix (Invitrogen) as per the manufacturer’s 
instructions. Real-time PCR reactions were carried out on an ABI prism 7900 (Applied 
Biosystems, Foster City, CA). CIITA promoter IV, CIITA exon IV, and CIITA exon VII were 
labeled 5’ with FAM reporter dye and 3’ with TAMRA quencher dye. Isolated DNA was 
analyzed by real-time PCR using primers spanning: 
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•CIITApIV promoter (Sense sequence, 5’-CAG TTG GGA TGC CAC TTC TGA-3’;  
Antisense sequence, 5’-TGG AGC AAC CAA GCA CCT ACT-3’;  Probe sequence, 5’-6 FAM-
AAG CAC GTG GTG GCC-3’TAM),  
•CIITApIV exon IV (Sense sequence 5’-TGC CCT AAT ACC TGA CGA CCA T-3’, 
Antisense sequence 5’-AAG CCC AAG GTG AGT CTC TAT TGT-3’, Probe sequence 5’-6 
FAM-CAG TCA GAC CCC TCT CCC CAA GGT G-3’TAM),  
•CIITApIV exon VII region (Sense sequence 5’-AAC ACA GCC CAC TTC CTC ACA-
3’, Antisense sequence 5’-AGC AGT CGC TCA CTG GTC TCA-3’, Probe sequence 5’-6 FAM-
ACT GTG GTG ACT GGC AG-3’ TAM), 
 •CD4 (Sense sequence, 5’-CAC AGG AAT GTG CTC TGC-3’, Antisense sequence 5’-
CAG TCT CTG ACC TCT GGA AG-3’, Probe sequence 5’-6 FAM-ACA GCT CTG GCC ACC 
TTC TCT TGC A-3’ TAM). 
 Values from real-time PCR reactions were calculated and graphed based on 
standard curves generated, were run in triplicate reactions, and were analyzed using the SDS 2.0 
program. 
 
2.3.10 Chromatin Immunoprecipitation with ATPase knockdown:  
HeLa cells were plated at a density of 2.5 X 106 in 10-cm tissue culture plates and were 
transfected with control siRNA or with ATPase-specific siRNA (Qiagen). Cells were stimulated 
with IFN-γ (500 U/ml) as indicated and 10% of the total cell volume was lysed with 1% Nonidet 
P-40 buffer with protease inhibitors and cell lysates were analyzed by Western blotting for 
ATPase knockdown specificity and efficiency. The remaining fraction of cell volume was 
subjected to ChIP assay as described above. 
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2.4 Results 
 
2.4.1 The proteasomal 19S ATPases Sug1, S7, and S6a are recruited to the CIITApIV 
proximal promoter 
We have previously shown that Sug1 associates with the MHC II promoter, regulates 
recruitment of CIITA and histone modifying enzymes to the promoter, and subsequently plays 
important roles in MHC II gene expression (Bhat, Turner et al. 2008). It has previously been 
demonstrated that yeast Rpt6 (Human Sug1) is required for efficient transcription elongation of 
RNA Pol II (Ferdous, Gonzalez et al. 2001). To analyze the role of the mammalian 19S ATPases 
in transcription elongation of additional genes, we evaluated whether Sug1 and other 19S 
ATPases influence transcription of inducible CIITApIV. ChIP assays were performed to 
determine whether ATPases Sug1, S7, or S6a directly bind to CIITApIV proximal promoters. 
HeLa cells were stimulated with IFN-γ, immunoprecipitated with antibodies to endogenous 
Sug1, S7, or S6a, and analyzed by real-time PCR with primers and probes spanning the 
CIITApIV promoter. Sug1, S7, and S6a associate with the CIITApIV promoter within 30 
minutes of IFN-γ stimulation and their binding is significant following two hours of stimulation 
(Figure 2.2A, C, E). These results indicate Sug1, S7, and S6a are inducibly recruited to the 
CIITApIV promoter. 
 
2.4.2 CIITA long transcripts are significantly decreased in the absence of 19S ATPases 
The 19S regulatory subunit of the 26S proteasome consists of six paired ATPases (Sug1 
and S6b; S7 and S4; and S6a and S10b), which recognize, unfold, and direct polyubiquitinated 
proteins towards the 20S proteolytic core for degradation. We have previously shown that 19S 
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ATPases (Sug1, S7, and S6a) co-immunoprecipitate with CIITA, regulate the binding of CIITA 
to the MHC II promoter, and promote transcription initiation of MHC-II genes (Bhat, Turner et 
al. 2008). To further understand the functions of these ATPases in the transcription of CIITApIV 
genes, CIITApIV mRNA was extracted from HeLa (human epithelial) cells which had been 
transfected with Sug1, S6a, or S7 siRNA duplexes in the presence and absence of IFN-γ 
stimulation. cDNA was prepared from the extracted mRNA using reverse primers specific for the 
CIITApIV exons IV and VII which correlate to short and long transcripts respectively; mRNA 
yields from specific samples were then quantified using real-time PCR. In cells transfected with 
Sug1 siRNA, the generation of both CIITApIV mRNA short and long transcripts is significantly 
reduced as compared to control siRNA treated cells (Figure 3A & 3B). Similarly, cells 
transfected with either S7 or S6a siRNA exhibit a reduced generation of short and long 
transcripts. In each instance the generation of CIITApIV long transcripts is significantly more 
impacted than is the generation of short transcripts indicating the impact of ATPase deficiency 
increases as transcription proceeds (compare Figure 2.3A & 2.3B; 2.3C & 2.3D; 2.3E & 2.3F). 
siRNA knockdown efficiency of the ATPases is shown in supporting information Figure S1A, 
S1B, and S1C.  
 
2.4.3 Effect of proteasome inhibition on CIITApIV transcription 
We previously demonstrated treatment of cells with S6a siRNA and Sug1 siRNA 
moderately reduces 26S mediated proteolysis (Koues, Dudley et al. 2008, Truax, Koues et al. 
2010). In the present work, the 26S proteasome inhibitors MG132 and Lactacystin were used to 
determine whether the negative effect of 19S ATPase knockdown on CIITApIV transcription is a 
result of inhibition of the proteolytic function of the proteasome. HeLa cells were stimulated 
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with IFN-γ and were treated with MG132 (10 µM) 4 hrs prior to harvesting. CIITA mRNA was 
extracted, and cDNA was generated using CIITApIV Exon IV and VII reverse primers; mRNA 
yields for exons IV and VII were then quantified by real-time PCR. Treatment of cells with 
MG132 increases the number of both short (Figure 2.4A) and long (Figure 2.4B) CIITA mRNA 
transcripts. Similarly, Lactacystin (10 µM) treatment of HeLa cells shows a similar increase in 
CIITA mRNA transcript levels (Figure 2.4C & 2.4D). These results indicate the role of 19S 
ATPases in the generation of CIITApIV mRNA transcripts is independent of the proteolytic 
function of the 26S proteasome. 
 
2.4.4 S6a siRNA does not activate heat shock response:  
Knockdown of 19S ATPases could also indirectly affect transcription by altering steady 
state protein levels and activating a heat shock response (Bush, Goldberg et al. 1997). To 
determine if 19S ATPase siRNA activates the heat shock response, HeLa cells were transfected 
with the Heat Shock Element (Reddy, Shenoy et al.) promoter tagged with Luciferase and with 
either control siRNA or S6a siRNA, or were treated with proteasome inhibitor MG132. Cells 
were harvested after 48 hrs incubation. The results shown in Figure 2.5 indicate a robust heat 
shock response in cells treated with MG132 and in cells transfected with the positive control, but 
no significant heat shock response in cells treated with S6a siRNA. Together these findings 
indicate that the effect of 19S ATPase siRNA in mediating reductions in CIITApIV mRNA 
transcripts is due to non-proteolytic roles of the 19S ATPases. 
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2.4.5 The 19S ATPases Sug1, S7, S6a bind within the coding region of CIITApIV gene 
To evaluate whether 19S ATPases move from promoters into actively transcribing 
mammalian genes, we investigated the binding of 19S ATPases to CIITApIV coding sequences 
using ChIP assays. We designed primers and probe sets spanning exons IV and VII of CIITApIV 
and performed ChIP assays in HeLa cells for Sug1, S7 and S6a. Cells were stimulated with IFN-
γ (0-2 hrs) as indicated and crosslinked and sonicated lysates were subjected to 
immunoprecipitation (IP) with antibodies against endogenous Sug1, S7, or S6a. Following IP, 
associated DNA was isolated and analyzed by realtime PCR using primers spanning CIITA exon 
IV and exon VII. Binding of Sug1 to CIITApIV exons IV and VII was observed over a time-
course of IFN-γ stimulation with significant binding at 2 hr and 0.5 hr respectively (Figure 2.6A 
& 2.6B). Similarly, 19S ATPases S7 and S6a bind to CIITApIV exon IV and exon VII over IFN-
γ stimulation with significant binding at 2 hr (Figure 2.6C, 2.6D & 2.6E, 2.6F). To probe for 
potential direct interactions between the 19S ATPases and DNA, gel mobility shift assays were 
conducted in which purified Myc tagged Sug1 was added to a 90 nt single-stranded DNA 
oligonucleotide. As shown in Figure 2.6G, lanes in which Sug1 is added to single stranded DNA 
exhibit a precipitant in the wells indicating an interaction with Sug1. Of note, similar assays with 
small double-stranded DNA oligonucleotides did not exhibit a similar precipitation (data not 
shown). Together these data indicate that the 19S ATPases bind to CIITA coding regions, 
supporting potential roles in RNA Pol II processivity. 
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2.4.6 The 19S ATPases Sug1, S7, S6a associate with components of the elongation factor 
PTEFb complex (Hexim and CDK9 
It was previously reported that the 19S ATPases associate with transcription factors and 
promote active transcription in yeast (Ferdous, Gonzalez et al. 2001). As the 19S ATPases bind 
to the CIITApIV proximal promoter, co-immunoprecipitation (co-IP) assays were used to 
determine whether the 19S ATPases also associate with transcription factors Hexim and CDK9 
which are required for productive elongation. Protein-protein interactions were initially 
determined using over expression co-IP assays in which HeLa cells were transfected with Myc-
tagged ATPases, with Flag-Hexim or HA-CDK9 and, following IP for either Flag-Hexim or HA-
CDK9, were then immunoblotted (IB) for Myc. The IP blot shown in Figure 7A indicates 
association of Hexim (lane 3) and CDK9 (lane 4) with Sug1. Similarly, the IP blots shown in 
Figure 2.7B & 2.7C indicate the association of S7 and S6a ATPases with Hexim (lanes 3) and 
CDK9 (lanes 4). The efficiency of transfections and equal loading of cell lysates was confirmed 
by immunoblot of Myc, HA, and Flag- tagged proteins. Co-immunoprecipitation experiments 
were next performed with endogenous proteins to determine if endogenous 19S ATPases (S6a, 
S7, Sug1) interact with endogenous Hexim and CDK9. Each of the endogenous 19S ATPases 
associate with Hexim (Figure 2.7D) while only endogenous S7 demonstrated pronounced 
interaction with CDK9 (Figure 2.7E).  Together these results demonstrate the 19S ATPases are 
in complexes with the Hexim1 and CDK9 components of PTEFb complex, which in turn 
regulates transcription elongation of CIITA genes. 
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2.4.7 The 19S ATPases associate with Ser5 phosphorylated-RNA pol II 
 Transcription in eukaryotes is initiated by the recruitment of RNA Pol II to promoter 
regions. RNA Pol II initiates synthesis of mRNA upon association with basal transcription 
factors and phosphorylation of its C terminal domain (CTD). Once preinitiation complexes form, 
RNA Pol II is phosphorylated on Serine 5 (Ser5p) by CDK7 of TFIIH and mRNA synthesis 
begins (Komarnitsky, Cho et al. 2000). A co-IP assay was performed to determine if 19S 
ATPases associate with Ser5p-RNA Pol II. HeLa cells were transfected with Myc-tagged 
ATPases, immunoprecipitated with Ser5p-RNA Pol II antibody, and immunoblotted for Myc. 
The IP blot shown in Figure 2.8A indicates association of expressed S6a, S7 and Sug1 ATPases 
with Ser5p-RNA Pol II (lanes 3, 6, 9). The efficiency of transfections and equal loading of cell 
lysates was confirmed by IB of Myc tagged proteins and of Ser5p-RNA Pol II. Analysis of co-IP 
of endogenous proteins also indicate association of each of the 19S ATPases with Ser5p-RNA 
Pol II (Figure 2.8B). Additional co-IP experiments with Ser2p-RNA pol II indicated only weak 
interactions (faint bands) between expressed S6a, S7, and Sug1 ATPases and Ser2p-RNA pol II 
(data not shown). Analysis of co-IP of endogenous proteins indicates strong association of 19S 
ATPases with Ser5p-RNA Pol II (Figure 2.8B).  
 
2.4.8 Knockdown of 19S ATPases decreases RNA Pol II phosphorylation but does not 
impact degradation 
Eukaryotic RNA Pol II consists of a C terminal domain composed of a series of heptad 
repeats (Dahmus 1996). The phosphorylation pattern of the CTD changes during transcription 
and serves as a flexible scaffold for binding nuclear factors required for specific transcription 
stages (Komarnitsky, Cho et al. 2000, Ahn, Kim et al. 2004). To understand if 19S ATPases 
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affect the regulation of RNA Pol II phosphorylation, we next determined the effect of 19S 
ATPase knockdown on levels of non-phosphorylated RNA pol II and on levels of 
phosphorylated RNA pol II (Ser2p-RNA Pol II and Ser5p-RNA Pol II). HeLa cells were 
transfected with control siRNA or with ATPase specific siRNA and 48 hrs later cell lysates were 
Immunoblotted using RNA Pol II, Ser2p-RNA Pol II, or Ser5p-RNA Pol II antibodies. The IB 
shown in Figure 2.9 (bottom panel) indicates there is no change in non-phosphorylated RNA pol 
II levels in 19S ATPase specific siRNA treated samples versus control siRNA treated samples 
and MB132 treated samples. In comparison, there is a decrease in levels of Ser5p-RNA Pol II 
and, to a lesser extent Ser2p-RNA Pol II (top and middle panels), in 19S ATPase siRNA treated 
samples versus control siRNA treated samples and MG132 treated samples. The knockdown 
efficiency and specificity of the 19S ATPase specific siRNA constructs is shown in supporting 
information Figure S2A and S2B.  
 
2.4.9 Knockdown of 19S ATPases Sug1, S7, or S6a decreases RNA Pol II and TBP 
recruitment to CIITApIV proximal promoter 
Regulation of protein coding genes is mediated by RNA Pol II and multiple transcription 
factors at various steps of the transcription process. Transcription initiation is accomplished by 
the recruitment of RNA Pol II to promoter sites and the formation of a pre-initiation complex 
with basal transcription factors (Nechaev and Adelman 2011). To assess whether the 19S 
ATPases aid in the recruitment of RNA Pol II to CIITApIV proximal promoters, ChIP assays 
(using antibody specific for RNA Pol II and primers and probe specific for the CIITApIV 
promoter region) were performed with cells treated with either control siRNA or with ATPase 
specific siRNA. As shown in Figure 2.10A, in cells treated with control siRNA, RNA Pol II 
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inducibly binds to the CIITApIV proximal promoter over a time course of IFN-γ stimulation. 
Cells transfected with Sug1 siRNA exhibit significantly decreased binding of RNA Pol II to the 
CIITApIV proximal promoter as compared to control siRNA treated samples. A similar trend 
was observed with S7 and S6a siRNA treated cells (Figure 2.10B, 2.10C). Efficiency of the 
knockdown of ATPase using siRNA is shown in supporting information Figure S3A, S3B, and 
S3C. Among the general transcription factors, TFIID factor is a complex composed of TATA 
binding protein (TBP) and TBP-associated factors (TAFIIS) and is required for transcription 
machinery. To assess whether the 19S ATPases aid in the recruitment of TBP to CIITApIV 
promoter, ChIP assays (using antibody specific for TBP and primers and probe specific for the 
CIITApIV promoter region) were performed with cells treated with either control siRNA or with 
ATPase specific siRNA. As shown in Figure 2.11A, in cells treated with control siRNA, TBP 
inducibly binds to the CIITApIV promoter over the time course of IFN-γ treatment. Cells 
transfected with Sug1siRNA exhibit significant decrease in binding of TBP to the CIITApIV 
promoter as compared to control siRNA treated cells. A similar trend was observed with S7 and 
S6a siRNA treated cells (Figure 2.11B, 2.11C). Efficiency of the knockdown of ATPase using 
specific siRNA is shown in supporting information Figure S4A, S4B and S4C. These studies 
indicate the 19S ATPases play critical roles in RNA Pol II and TBP recruitment at CIITA genes. 
 
 
2.5 Discussion 
Proteasomal proteins are crucial regulators of transcriptional activities both dependent on, 
and independent of, protein degradation. While the stage is set for novel developments in our 
understanding of gene expression, the roles of individual proteasome components in transcription 
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remain to be determined. The 19S ATPases were initially found to associate with actively 
transcribed genes and to facilitate recruitment of transcription factors to active genes in yeast 
where 19S ATPases play important, but undefined, roles in RNA Pol II dependent elongation 
(Ferdous, Gonzalez et al. 2001). We have previously demonstrated that binding of 19S ATPases 
at the mammalian MHCII promoter mediates transcription initiation by stabilizing the binding of 
activating histone modifying enzymes and transcription factors (Bhat, Turner et al. 2008, Truax, 
Koues et al. 2010). We show now that representatives of each of the 19S ATPase heterodimers 
are inducibly recruited to another mammalian gene, the CIITApIV promoter (Figure 2.2) and, 
that upon activation of transcription, 19S ATPases move into CIITApIV exons (Figure 2.6).  
 
Since chromatin structure was recognized as repeating units of histones and DNA in 
nucleosome cores, it has been proposed that the function of chromatin is to regulate transcription 
(Li, Carey et al. 2007). Chromatin regulators transiently remodel chromatin in response to 
cellular signals in order to change the accessibility of DNA to transcription factors and 
polymerases (Saha, Wittmeyer et al. 2006). As the 19S ATPases bind throughout CIITApIV 
genes, our initial focus was to determine the impact of the ATPases on the generation of 
transcripts from CIITApIV. Depletion of the 19S ATPases Sug1, S7, or S6a decreases IFN-γ 
induced transcription of CIITApIV with significant impact on the generation of longer 
CIITApIV transcripts (Figure 3). These observations indicate the 19S ATPases are involved in 
regulating chromatin: in the absence of 19S ATPases, the further the polymerase has to move, 
the more difficult the journey ahead. 
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Depleting 19S ATPases might lead to the malfunction of the proteasome and therefore 
impair degradative processes. To address this concern, we previously demonstrated that 
degradation continues in cells in which 19S ATPases have been knocked down (Koues, Dudley 
et al. 2008). These data support recent findings of the existence of cellular pools of 19S ATPases 
and also support our hypothesis that 19S ATPases have non-proteolytic roles in regulating 
transcription. We extend these observations here by demonstrating that while 19S ATPase 
knockdown inhibits CIITApIV transcription, inhibition of proteasome activity significantly 
increases CIITApIV transcription (Figure 2.4). These data further indicate the 19S ATPases have 
functions that are independent of proteasome activity but which are essential in the regulation of 
transcription. Our current findings also support our previous observations that unlike ATPase 
knockdown, proteasome inhibition does not affect the regulation of acetylation and methylation 
of histones H3 and H4 (Bhat, Turner et al. 2008, Koues, Dudley et al. 2008, Koues, Dudley et al. 
2009, Koues, Mehta et al. 2010, Truax, Koues et al. 2010).  
 
Finally, very efficient knockdown of 19S ATPases could lead to the accumulation of mis-
folded and partially degraded proteins, and the activation of a heat shock response, similar to that 
caused by temperature induced protein mis-folding (Kettern, Dreiseidler et al. 2010). We observe 
here however that siRNA mediated knockdown of the 19S ATPases does not activate a heat 
shock response (Figure 2.5). Together these data also indicate the effects of 19S ATPase 
knockdown on transcription of CIITApIV are direct, are due to nondegradative roles for 19S 
ATPases, and are not the result of dysregulated proteolysis.  
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The expression of protein coding genes is carried out by RNA Pol II and various 
transcription factors (Buratowski 1994) and is controlled at multiple levels (Conaway and 
Conaway 1993, Roeder 1996). RNA Pol II escape from promoter regions and the transition of 
RNA Pol II to an elongating complex is highly regulated and specific phosphorylation events of 
the RNA Pol II CTD (C-terminal domain) are required for transcription initiation and elongation 
(Sims, Belotserkovskaya et al. 2004, Hager, McNally et al. 2009). RNA Pol II Ser 5 
phosphorylation is required for the transition from initiation to elongation whereas Ser 2 
phosphorylation is required for elongation (Hager, McNally et al. 2009). These phosphorylation 
events are mediated by kinase TFIIH (CDK7), the mediator complex, and the kinase PTEF-b 
(CDK9). As the 19S ATPases are required for transcription from CIITApIV, we next determined 
if these ATPases associate with transcription elongation factors and with the phosphorylated 
forms of RNA Pol II.  
 
We first showed that the 19S ATPase Sug1 interacts with DNA (Figure 6G) and that both 
tagged and endogenous proteins (ATPases Sug1, S7, and S6a) interact with components of 
PTEFb and with Ser5p-RNA Pol II (Figure 2.7 & 2.8). Variation in the intensity of interactions 
seen in co-IP experiments is evidence of the independent functions of 19S ATPases in regulating 
transcription (Sledz, Unverdorben et al. 2013). PTEF-b exists in two forms, active and inactive, 
where the inactive form of PTEF-b is bound to Hexim1 and 7SK RNA. Upon cytokine 
stimulation, PTEF-b is dissociated from the inactive complex bound by Hexim-1 and 7SK RNA 
and is recruited to actively transcribing genes (Koues, Dudley et al. 2008, Rabl, Smith et al. 
2008, Koues, Mehta et al. 2010). Association of 19S ATPases with factors and complexes 
associated with transcription elongation was not surprising as the ATPases were found 
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distributed throughout CIITApIV exons. It is noteworthy that Ser2p of RNA Pol II is required for 
maintaining both global and gene associated levels of H2B monoubiquitination as previous work 
by Ezhkova and Tansey has shown that H2B K123 ubiquitination is required to recruit 19S 
ATPases (Ezhkova and Tansey 2004). There is also evidence indicating that the 19S regulatory 
particle base is required for SAGA recruitment and that particularly the 19S ATPase Sug1 
interacts with the SAGA complex and aids in transcription (Lee, Ezhkova et al. 2005). Together, 
these data suggest the 19S ATPases are recruited to promote chromatin reconfiguration and 
binding of histone modifiers to actively transcribing genes. The 19S ATPase S7 was strongly 
associated with endogenous Ser5 phosphorylated-RNA Pol II (Figure 2.8). While 19S ATPase 
knockdown had no impact on global RNA Pol II levels, there was a specific decrease in levels of 
Ser5p-RNA Pol II in lysates from each of the ATPase knock down cells (Figure 2.9). Together 
these data suggest variable roles for the 19S ATPases in transcription initiation or in the 
transition of RNA Pol II to a productive elongation phase.  
 
It has been proposed that the 19S ATPases participate in nucleosome eviction and 
chromatin remodeling necessary to release paused RNA Pol II (Ferdous, Gonzalez et al. 2001, 
Chaves, Baskerville et al. 2010). As the 19S ATPases associate with DNA, with elongation 
factors and with the promoter region of CIITApIV, we determined whether the 19S ATPases are 
involved in the recruitment of RNA Pol II to the CIITApIV promoter for phosphorylation and 
subsequent elongation. RNA Pol II and TBP binding to CIITApIV was significantly reduced in 
the absence of 19S ATPases (Figure 2.10) while mRNA levels were less impacted by 19S 
ATPase knockdown (Figure 2.3). The relative difference in impact on RNA Pol II recruitment 
versus mRNA expression suggests that low level recruitment of RNA Pol II to CIITApIV drives 
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modest transcription of CIITA, albeit with greater difficulty the further down the CIITApIV gene 
the polymerase must transcribe. RNA Pol II overcomes nucleosome barriers with closely spaced 
transcribing RNA Pol II displacing core histones and promoting transcription. While the density 
of RNA Pol II molecules bound to CIITApIV affects rates of transcription, impaired 
transcription persists in the absence of 19S ATPases. Together, these studies indicate the 19S 
ATPases play roles in recruitment and/or processivity of RNA Pol II at CIITApIV genes. Indeed, 
recent studies of the holo RNA Pol II complex indicate the mediator complex contains the 19S 
ATPase Sug1 (Kim, Bjorklund et al. 1994); together with our findings, these data indicate 
multiple roles for the 19S ATPases in the regulation of transcription elongation.  
 
Further delineation of the specific mechanisms by which individual 19S ATPases 
influence transcription will provide information about the complex role of the ATPases in the 
stages of transcription. As a part of the 26S proteasome complex, only the S6a ATPase binds the 
polyubiquitinated chains of substrates targeted for proteasome mediated degradation (Lam, 
Lawson et al. 2002) and S6a alone binds the coding region of the human immunodeficiency virus 
type 1 gene in the presence of the transcription factor Tat (Lassot, Latreille et al. 2007). During 
protein degradation, yeast 19S ATPases Rpt1, Rpt2, and Rpt6 (human S7, S4, and Sug1, 
respectively) provide the pulling force by which substrates unfold and are pulled inwards toward 
the 20S core while the remaining 19S ATPases, Rpt3, Rpt4, and Rpt5, (human S6b, S10b, S6a, 
respectively) stabilize the substrate and translocate it towards the 20S core for degradation 
(Sledz, Unverdorben et al. 2013). Our data now indicates the S7 ATPase interacts strongly with 
CDK9 and with Ser5p RNApol II. Thus the possibility remains that despite the similar impact of 
knockdown of Sug1, S7, and S6a on transcription at CIITApIV, the 19S ATPases may have 
63 
independent functions in transcription. In fact, only the 19S ATPase S6a has previously been 
shown to contain bona fide ATPase activity (Nelbock, Dillon et al. 1990); and it is the S6a 
ATPase motif, but not the S6a helicase motif, which is necessary to enhance transactivation of 
inducible genes (Ishizuka, Satoh et al. 2001). It remains to be determined if a similar ATP driven 
unwindase activity, and potentially some unique activity of S6a and/or other 19S ATPases, is 
utilized to drive requisite conformational changes in histones, in transcription factors, and/or in 
coactivators to regulate their interactions with promoters and coding sequences and to allow 
transcription processes to occur.  
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Figure 2.1 .1 The 26S proteasome  
The 26S proteasome is composed of a 20S proteolytic core capped on one or both ends by 19S 
regulatory particle. The 20S core is a hollow cylindrical structure composed of two heptameric 
rings of α-subunits and two heptameric rings of β-subunits. The 19S regulatory particle is 
composed of a base and lid component. The lid component consists of nine non-ATPase subunits 
and the base is composed of six ATPases (S7, S4, S6a, S10b, Sug1 and S6b) and three non-
ATPases (S1, S2, and S5b). Polyubiquitinated proteins are recognized, deubiquitinated, and 
unfolded by the 19S regulatory particle and the unfolded proteins are translocated to the 20S core 
where proteins are degraded into small peptides 
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Figure 2.2 19S ATPases associate with the CIITA pIV proximal promoter 
(A, C,E) ChIP assays were carried out in HeLa cells stimulated with IFN-γ for 0-2 hrs. Cell 
lysates were immunoprecipitated (IP’d) with control antibody or with antibody to endogenous 
19S ATPase S6a, Sug1, or S7 and associated DNA was isolated and analyzed by real-time PCR 
using primers and probe spanning the CIITApIV proximal promoter. Real time PCR values were 
normalized to the total amount of DNA in the reaction (Input). IP values are represented as 
ATPase binding to CIITApIV promoter DNA relative to unstimulated samples. (B,D,F) ChIP 
signal at the inactive gene CD4. The control IgG values were 0.004 ± 0.001. Values for control 
IgG and either Sug1 IP, S7 IP or S6a IP represent the mean ± SEM of three biologically 
independent experiments * p < 0.05. 
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Figure 2.3 Reduced expression of 19S ATPases via siRNA negatively impacts the 
generation of long transcripts from CIITA pIV 
(A-B, D-E, G-H) Cells were transfected with siRNA, and mRNA was quantitated using CIITA 
mRNA primers and probes specific for transcripts from CIITA exon IV and exon VII. CIITA 
mRNA generated was normalized to GAPDH. Data shown represent the mean ± SEM of three 
biologically independent experiments. (C, F, I) Expression of Sug1, S7, and S6a was specifically 
decreased using ATPase specific siRNA (Supporting information Figure S1A, S1B, and S1C). 
Blots shown are representative of three biologically independent experiments.  
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Figure 2.4 Effects of 19S ATPase knockdown on CIITApIV transcription are independent 
of effects on degradation. 
(A-B, D-E) HeLa cells were stimulated with IFN-γ as indicated and were harvested four hrs post 
treatment with 10 µM MG132 or 10 µM Lactacystin. mRNA was extracted and cDNA was 
generated using indicated reverse primers followed by amplification via real-time PCR.  CIITA 
mRNA transcripts were obtained using primers and probes specific for CIITA exon IV and exon 
VII were normalized to GAPDH. (C) 18S rRNA transcripts for control and MG132 treated cells 
were obtained using primers and probe specific for 18S rRNA and were normalized to GAPDH. 
The 18 hr control sample was set to 100%. Data shown represents the mean ± SEM of three 
biologically independent experiments.  
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Figure 2.5 Knockdown of 19S ATPases does not activate the heat shock response 
HeLa cells were transfected with HSE-Luciferase reporter, control siRNA, or S6a siRNA and 
were treated with MG132 six hrs prior to harvest. Cells were harvested following 48 hrs of 
incubation, lysed in cell lysis buffer, and analyzed by Luciferase assay. Luciferase readings 
obtained were normalized by Bradford assay. Data shown represents values obtained from three 
independent experiments. The negative control is a mixture of non-inducible reporter construct 
and constitutively expressing Renilla luciferase construct. The positive control is an inducible 
transcription factor-responsive construct expressing firefly luciferase, and a constitutively 
expressing Renilla luciferase construct. 
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Figure 2.6 19S ATPases bind CIITA pIV within the coding region 
ChIP assays were carried out in HeLa cells stimulated with IFN-γ for 0-2 hrs. Cell lysates were 
IP’d with control antibody or with antibody to endogenous Sug1 (A and B), S7 (D and E), or S6a 
(G and H) and associated DNA was isolated and analyzed by real-time PCR using primers and 
probes spanning CIITApIV exon IV (A, C, E) and exon VII (B, D, F). Real time PCR IP values 
were normalized to the total amount of DNA (input); IP values are represented as ATPase 
binding to CIITApIV exon IV or exon VII DNA relative to unstimulated samples.  (C,F,I) ChIP 
signal at the inactive gene CD4. The control IgG values were 0.005 ± 0.001. Values for control 
and IP represent mean ±SEM of three biologically independent experiments. *p < 0.05, 
**p<0.005. G. Mobility shift assay of Sug1 with a 90 nucleotide single stranded DNA on a 
native 8% polyacrylamide gel with a tris-borate magnesium running buffer; 0.7 µM DNA, 0.85 
µM sug1, and 500 µM ATP. DNA was visualized with SYBER Green II dye.  
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Figure 2.7 19S ATPases associate with elongation factors Hexim and CDK9 
(A-C) HeLa cells were co-transfected with Myc tagged S6a, S7, or Sug1 and Flag tagged Hexim 
or HA tagged CDK9 as indicated. Cells were lysed and Immunoprecipitated with Myc beads 
(lane 1) as a positive control, mouse isotype IgG (lane 2) as a negative control, flag beads (lane 
3), and HA beads (lane 4). IP samples (top panel) and lysates (bottom panel) were 
Immunoblotted for Myc, Flag, and HA as indicated. (D-E) HeLa cells were lysed and 
Immunoprecipitated with either Hexim or CDK9 (lane 1) as a positive control, mouse isotype 
IgG (lane 2) as a negative control, or with S6a (lane 3), S7 (lane 4), and Sug1 (lane 5).  IP 
samples (top panel) and lysates (bottom panel) were Immunoblotted for Hexim or CDK9 as 
indicated. Results shown are indicative of data from three biologically independent experiments. 
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Figure 2.8 19S ATPases associate with Ser5 phosphorylated RNA pol II (Ser5p-RNA pol 
II). 
(A) HeLa cells were transfected with myc tagged S6a, S7 or Sug1 as indicated. Cells were lysed 
and Immunoprecipitated with myc beads (first lane, top panels) as a positive control, with mouse 
isotype IgG (second lane, top panels) as a negative control, and with Ser5p-RNA Pol II antibody 
(third lane, top panels). Immunoprecipitated samples (top panels) and lysates (middle and bottom 
panels) were IB for myc ATPases or for Ser5p-RNA pol II as indicated. (B) HeLa cells were 
lysed and Immunoprecipitated with Ser5p-RNA Pol II (lane 1) as a positive control, mouse 
isotype IgG (lane 2) as a negative control, or with S6a (lane 3), S7 (lane 4), or Sug1 (lane 5). IP 
samples (top panel) and lysates (bottom panel) were Immunoblotted Ser5p-RNA Pol II as 
indicated. Results shown are indicative of data from three biologically independent experiments. 
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Figure 2.9 Reduced expression of 19S ATPases decreases phosphorylated forms of RNA 
Pol II. 
 (A.) HeLa cells were transfected with siRNA or were treated with proteasome inhibitors as 
indicated. Cells were harvested following 48hrs of siRNA incubation. Cell lysates were 
Immunoblotted with Ser2p-RNA pol II antibody (top panels), Ser5p-RNA pol II (middle panels), 
or with RNA pol II antibody (bottom panels). Cells treated with proteasome inhibitors serve as a 
positive control for degradation dependent effects. Results shown are indicative of data from 
three biologically independent experiments. Sug1, S7, and S6a protein expression was 
effectively decreased using specific siRNA. Actin blots demonstrate loading and siRNA 
specificity controls (Supporting information Figure S2A and S2B). 
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Figure 2.10 Reduced expression of 19S ATPases decreases RNA pol II recruitment to the 
CIITApIV proximal promoter 
 (A,C,E) ChIP assays were carried out in HeLa cells transfected with ATPase specific or with 
control siRNA and stimulated with IFN-γ for 0-2 hrs. Cell lysates were crosslinked, sonicated, 
lysed, and IP’d with either antibody against endogenous RNA pol II or with control antibody 
(IgG). Associated DNA was analyzed via real-time PCR using primers and probe specific for the 
CIITApIV proximal promoter. Real time PCR IP values were normalized to total amount of 
reaction DNA (Input). The values for control IP and RNA Pol II IP represent the mean of three 
biologically independent experiments *p<0.05, **p<0.005, ***p<0.0005 versus control siRNA. 
(B, D, F) ChIP signal at the inactive gene CD4. Sug1, S7, and S6a protein expression was 
effectively decreased using ATPase specific siRNA (Supporting information Figure S3A, S3B, 
and S3C).  
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Figure 2.11 Reduced expression of 19S ATPases decreases TBP recruitment to the 
CIITApIV proximal promoter 
(A, C, E) ChIP assays were carried out in HeLa cells transfected with ATPase specific or with 
control siRNA and stimulated with IFN-γ for 0-2 hrs. Cell lysates were crosslinked, sonicated, 
lysed, and IP’d with either antibody against endogenous TBP or with control antibody (IgG). 
Associated DNA was analyzed via real-time PCR using primers and probe specific for the 
CIITApIV proximal promoter. Real time PCR IP values were normalized to total amount of 
reaction DNA (Input). The values for control IP and TBP IP are representative data *p<0.05, 
**p<0.005, ***p<0.0005 versus control siRNA. (B, D, F) ChIP signal at the inactive gene CD4. 
Sug1, S7, and S6a protein expression was effectively decreased using ATPase specific siRNA 
(Supporting information Figure S4A, S4B, and S4C).  
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3.1 Abstract 
Microglial cells are brain resident macrophages  which  are activated by toxic metabolites 
released from damaged neurons and help in cleaning the cellular debris, apoptotic cells and help 
in mainitaining homeostasis in the central nervous system (CNS).  But excessive activation leads 
to release of reactive oxygen species such as nitric oxide, superoxides and pro-inflammatory 
cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) which promote 
neurotoxic effects and leads to neuroinflammation in the CNS. Regulator of G-protein signaling 
10 (RGS10) is abundantly expressed in microglia and it was found to play critical role in 
regulating neuroinflammatory responses in the brain. Recent evidence shows that brains of 
RGS10 knockout mice exhibit increased microglial activation, increased cytokine production, 
and higher vulnerability toward neuroinflammation-induced neuronal cell death, suggesting 
RGS10 is a key anti-inflammatory regulator. However, the mechanism by which RGS10 exerts 
its anti-inflammatory effects in microglia are unknown.  
We investigated here the molecular mechanisms by which RGS10 promotes anti-
inflammatory properties in the CNS by negatively regulating NF-κB in BV2 microglial cells. 
Our results suggest that RGS10 associates with pro-inflammatory cytokine gene promoters TNF-
α and IL-1β, providing novel mechanism for RGS10 protein effects. We performed gel shift 
assays to determine associations of RGS10 with IL-1β gene promoter, but could not identify the 
interaction of RGS10 with DNA. Further we performed NF-κB transcription factor assay to 
determine whether RGS10 binds to NF-κB binding site and the results indicated that RGS10 
does not bind to NF-κB response element. We next analyzed whether RGS10 interacts with NF-
κB and regulates NF-κB under LPS stimulation but our results indicate there is no direct 
association between RGS10 and NF-κB. Together our findings contribute significantly to 
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understanding the non-canonical role of RGS10 in regulating proinflammatory cytokine genes 
but the specific molecular target or mechanism of association remains to be explored. 
 
3.2 Introduction 
Neuroinflammation caused by dysregulated microglial activation in the central nervous 
system is the common cause for initiation and progression of several neurodegenerative diseases 
including Multiple Sclerosis, Alzheimers, Parkinsons (Fu, Shen et al. 2014) (Tansey, McCoy et 
al. 2007) and Neuropathic pain (Campbell and Meyer 2006) (von Hehn, Baron et al. 2012). 
Multiple Sclerosis is an autoimmune disorder which affects 6% of the US population and is the 
third largest disease burden after heart disease and cancer (Swanberg, Lidman et al. 2005, 
Siatskas, Chan et al. 2006). Alzheimers is the sixth leading cause of death in the US and is 
particularly observed in individuals over 65 years of age (Tejada-Vera 2013) (Hebert, Weuve et 
al. 2013). Neuropathic pain is chronic pain caused by dysfunction of the peripheral or central 
nervous system (von Hehn, Baron et al. 2012) and affects 28 to 65% of US adults (Yawn, 
Wollan et al. 2009) (Gilron, Baron et al. 2015). Parkinsons Disease is the second most common 
neurodegenerative disorder following Alzheimers in the United States with an estimated 
prevelance of 0.3% in general population which  increases up to 2% for individuals over the age 
of 65 (Kowal, Dall et al. 2013) (Weintraub, Comella et al. 2008).  
 
Overall, these neurologic disorders affect millions of individuals in the United States and 
largely have an unknown cause but known immune involvement (Hirtz, Thurman et al. 2007). 
Thus understanding the molecular mechanisms driving the regulation of neuroinflammation in 
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the central nervous system will enable us to improve current therapeutic targets for not only 
multiple sclerosis, but also for other neurodegenerative diseases. 
 
Microglia are brain resident macrophages and immune protective cells in the central 
nervous system (Tambuyzer, Ponsaerts et al. 2009) which are distributed in various regions of 
the brain in both humans and in mice (Mittelbronn, Dietz et al. 2001). In the resting state 
microglia have ramified morphology and monitor the brain region. Activated microglia undergo 
transformation from ramified state into an amoeboid morphology and present several cell surface 
molecules such as major histocompatibility complex molecules, chemokine receptors (Cho, Song 
et al. 2006) and promote neuronal survival through the release of anti-inflammatory factors 
(Morgan, Taylor et al. 2004) (Muller, Snyder et al. 2006). Microglia also facilitate repair by 
promoting the migration of stem cells to the site of inflammation (Aarum, Sandberg et al. 2003). 
Microglia have pattern-recognition receptors of toll-like receptor family (TLR family) which 
detect signal molecules released from damaged neurons and microbial derived molecules such as 
lipopolysaccharide (LPS), lipoteichoic acaid, peptidoglycan (PGN) and unmethylated bacterial 
DNA (Olson and Miller 2004) (Dalpke, Schafer et al. 2002). 
 
Microglia are activated by signs of damage or infection or other stimuli that threaten 
neuronal survival and are responsible for protective and homeostatic function by clearing cellular 
debris and infected cells in the CNS (Domercq, Vazquez-Villoldo et al. 2013) (Streit 2000). 
Overactivation of microglial cells induces production of several cytotoxic factors such as 
superoxides, nitric oxide and tumor necrosis factor-alpha and promotes neurotoxic effects and 
leads to neuroinflammation in the CNS (Block, Zecca et al. 2007) (Streit 2000).  
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Activated microglia are present in large numbers in neurodegenerative diseases, a 
condition called microgliosis, strongly indicating their role in disease pathology (Domercq, 
Vazquez-Villoldo et al. 2013). LPS induced microglial activation both in vivo and in vitro is 
shown to be neurotoxic and promotes progressive loss of dopaminergic neurons, indicating that 
microglia can initiate neuronal damage (Ling, Zhu et al. 2006) (Gibbons and Dragunow 2006). 
Thus, microglia can be overactivated by environmental toxins and, endogenous mediators 
released by damaged neurons in turn damage surrounding neurons termed as reactive 
microgliosis, thus promoting chronic neuroinflammation in the CNS (Gibbons and Dragunow 
2006). 
 
It recently was shown that microglia assist in creating a microenvironment suitable for 
neural repair and regeneration of the demylinated nerve fibers observed in multiple sclerosis 
(Napoli and Neumann 2010). Therefore, microglial activation is required for host 
defense,neuronal survival (Morgan, Taylor et al. 2004) (Muller, Snyder et al. 2006) and for 
overactivation of microglia; all resulting in neurotoxic effects (Lull and Block 2010) (Domercq, 
Vazquez-Villoldo et al. 2013).  Therefore understanding the causes of chronic microglial 
activation, the key factor for inflammation in the CNS, will provide insight into aetiology, 
pathogenesis, the  identification of molecular targets for treating neurodegenerative disease.  
 
Regulator of G-protein signaling (RGS) proteins are a diverse group of proteins that 
regulate signaling pathways downstream of G-protein coupled receptors and which have recently 
been implicated in neurodegenerative disease. The RGS proteins accelerate GTP hydrolysis and 
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serve as negative regulators of G-protein signaling by promoting deactivation of G-proteins 
(Ross and Wilkie 2000) (Siderovski, Diverse-Pierluissi et al. 1999) (Hurst and Hooks 2009) 
(Kach, Sethakorn et al. 2012). The RGS proteins vary in their size and contain structural domains 
that help in identifying binding partners that regulate their activity (Ross and Wilkie 2000). RGS 
proteins were identified in the brain (Gold, Ni et al. 1997), retina (Hollinger and Hepler 2002) 
(Arshavsky and Pugh 1998), and heart (Hollinger and Hepler 2002) and the G-protein signaling 
occurs much faster in these tissues (Arshavsky and Pugh 1998). RGS proteins localize to the 
membrane (Roy, Lemberg et al. 2003) (Srinivasa, Watson et al. 1998), nucleus (Chatterjee and 
Fisher 2000), cytoplasm (Chatterjee and Fisher 2000) and shuttle between nucleus and cytoplasm 
as nucleo-cytoplasmic shuttle proteins; indicating a possibility to be involved in various cellular 
processes (Chatterjee and Fisher 2000). 
 
Regulator of G-protein signaling 10 (RGS10) is a 20KD protein which belongs to the 
D/R12 subfamily. RGS10 is enriched in microglia (Waugh, Lou et al. 2005) and is also found in 
a subset of neurons, and was recently found to play a critical role in regulating microglial 
activation and neuroinflammatory responses in the brain (Waugh, Lou et al. 2005).  A lack of 
RGS10 expression in mice increases microglial cell activation in the CNS, leading to chronic 
systemic inflammation and degeneration of dopaminergic neurons (Lee, McCoy et al. 2008) 
(Lee, Chung et al. 2011).  
 
RGS10 protein expression is observed in both nuclear and cytoplasmic compartments of 
microglial cells (Waugh, Lou et al. 2005) and Serine 168 phosphorylation of RGS10 promotes 
translocation of RGS10 to the nucleus (Burgon, Lee et al. 2001). RGS10 negatively regulates the 
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transciription factor NF-κB and  regulates transcription of multiple pro-inflammatory mediators 
such as IL-1β and TNF-α cytokine genes (Lee, Chung et al. 2011). However, the mechanism by 
which RGS10 controls gene trabscription and whether this reflects a direct action in the nucleus 
is unknown. Thus, identifying molecular regulators of microglial activation will help in 
understanding neuroinflammatory mechanisms that effect homeostatic condition in the CNS.  
 
We investigate here the molecular mechanisms by which RGS10 promotes anti-
inflammatory properties in the CNS by negatively regulating NF-κB in BV2 microglial cells. We 
identify that RGS10 associates with IL-1β and TNF-α promoters, but that this association is 
decreased following activation with LPS treatment. Similarly, there is an increase in recruitment 
of NF-κB at IL-1β and TNF-α promoters in LPS treated samples when compared to untreated 
cells. Our results suggest that RGS10 interacts with promoter regions of IL-1β and TNF-α, but 
the specific molecular target or mechanism of association remains undefined. Our data rule out 
direct association of RGS10 to promoter DNA or interaction with the NF-κB target site, but 
ongoing studies will explore whether RGS10 might be involved in a molecular complex that 
binds to promoter DNA of proinflammatory cytokine genes such as IL-1β.  
3.3 Materials and Methods 
3.3.1 Cell Lines and Reagents 
BV2 microglial cell line was maintained in DMEM medium (Mediatech Inc.) 
supplemented with 10% FBS, 5 mM penicillin-streptomycin and 5 mM L-glutamine. Cells were 
grown in at 37°C with 5% CO2.  
Lipopolysaccharide (LPS) was purchased from Sigma-Aldrich (St. Louis). Gel shift 
antibodies recognizing RGS10, NF-kB, donkey-anti-goat IgG-HRP (Horseradish peroxidase), 
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HRP conjugated rabbit antibodies, Western blot antibodies recognizing RGS10, NF-kB were 
obtained from Santa Cruz (Santa Cruz, CA). ChIP grade antibody recognizing NF-kB was 
obtained from Abcam (Cambridge, MA). HRP conjugated mouse antibodies were purchased 
from Promega (Madison, WI). Antibodies recognizing β-Actin and Histone H3 were obtained 
from Cell Signaling (Beverly, MA). Oligonucleotide1, oligonucleotide2, unlabeled 
oligonucleotide2 sequences were obtained from Integrated DNA Technologies Inc (IDT) 
(Coralville, IA) 
3.3.2 Electrophoretic mobility shift assay 
The nuclear proteins from untreated microglial cell lines were prepared using the nuclear 
extraction kit from Affymetrix (AY2002) as per manufacturer’s instructions. 1 µg of nuclear 
proteins were used in an EMSA reaction using Biotin end labeled IL-1β double stranded 
oligonucleotide (Affymerix, AY1000, EMSA kit). The biotin end labeled oligonucleotide1 
sequence (5’- CAC TTC TGC TTT TTA GGA CTA TAA AAC AAG GGA GGG /3Bio/-3’). 
The biotin end labeled oligonucleotide2 sequence (5′- GAA ATC AGT TAA CCC AAG GGA 
AAA TTT CAC AGC TCT TCA C/3Bio/ -3'). The unlabeled oligonucleotide2 sequence  (5′- 
GAA ATC AGT TAA CCC AAG GGA AAA TTT CAC AGC TCT TCA C/-3') was used for 
competition reaction. The nuclear proteins and labeled oligonucleotide or excess unlabeled 
oligonucleotide were incubated for 20 minutes at room temperature, separated on 5% non-
denaturing polyacrylamide gel and transferred onto nitrocellulose membrane and detected 
following manufacturer’s instructions. The EMSA using HeLa cell nuclear extract provided in 
the kit was used as positive control and IgG, nuclear extract alone, oligonucleotide alone served 
as negative controls respectively. 
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3.3.3 Chromatin Immunoprecipitation  Assay 
ChIP assays were performed as previously described (Maganti, Moody et al. 2014). 
Briefly, cells were plated at a density of 2 x 106 in 10cm2 plates. Three million cells were 
crosslinked with 1% formaldehyde for eight minutes at room temperature. Crosslinking reactions 
were stopped by the addition of 0.125M glycine. Cell nuclei were isolated and were concentrated 
by lysis in SDS lysis buffer (1% SDS, 10mM EDTA, 50mM Tris pH 8.0) plus protease inhibitors 
for 30 minutes on ice followed by flash freezing in liquid nitrogen. Nuclei were sonicated using a 
Bioruptor water bath sonicator (Diagenode) to generate an average of 500bp of sheared DNA 
which was confirmed by agarose gel electrophoresis. Sonicated lysates were precleared with 
salmon-sperm/agarose beads (Millipore), 5% of the total lysate was stored as input for 
normalization. Half of the remaining lysate was immunoprecipitated with 5µg of RGS10 
antibody overnight at 4°C and the other half of the lysate was immunoprecipitated with a mouse 
IgG control antibody. Following an additional two hour immunoprecipitation with salmon-sperm 
coated agarose beads, all samples were washed with each of the following buffers: low salt 
buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.0, 150mM NaCl), high salt 
buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.0, 500mM NaCl), LiCl 
(0.25M LiCl, 1% NP40, 1% DOC, 1mM EDTA, 10mM Tris pH 8.0), and 1xTE (Tris-EDTA); 
DNA was then eluted with SDS elution buffer (1% SDS, 0.1M NaHCO3). Following elution, 
cross-links were reversed overnight with 5M NaCl at 65°C and the immunoprecipitated DNA 
was isolated using phenol:chloroform:isopropanol mix  (Invitrogen) as per the manufacturer’s 
instructions. Isolated DNA was quantified by real time PCR on an ABI prism 7900HT (Applied 
Biosystems, Foster City, CA) using specific primers and probes targeting IL-1β, TNF-α and 
GAPDH promoters region. Primers used were IL-1β Forward: 5’-AAG CAC AAG GAG GCG 
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AGA GA-3’; IL-1β Reverse: 5’-AGG ATG TGC GGA ACA AAG GT-3’; IL-1β Probe: 5’-6 
FAM-CAC TTC TGG GTG TGC ATC TAC GTG CC-3’TAM, TNF-α Forward: 5’- CCG AGG 
GTT GAA TGA GAG CTT-3’; TNF-α Reverse: 5’- AGA CGG CCG CCT TTA TAG C-3’; 
TNF-α Probe: 5’-6 FAM-TCC CCG CCC TCT TCC CCA AG-3’TAM, GAPDH: Forward, 5’-
AAT GAA TGG GCA GCC GTT A-3’, Reverse, 5’-TAG CCT CGC TCC ACC TGA CT-3’ and 
Probe, 5’-6 FAM-CCT GCC GGT GAC TAA CCC TGC GCT CCT-3’TAM. Values generated from 
real time PCR reactions were calculated based on standard curves generated, were run in 
triplicate reactions, and were analyzed using the SDS 2.0 program (Applied Biosystems).  
 
3.3.4 Endogenous Co-Immunoprecipitation 
BV2 cells were plated at a cell density of 8 X 105 cells/10cm2 tissue culture plates. 
Following adhesion, the cells were harvested and lysed with 1% NP40 supplemented with 
EDTA- free protease inhibitor (Roche) on ice. Cells were pre-cleared with mouse IgG (Sigma) 
and Protein G (Thermo Fisher) followed by immunoprecipitation with RGS10 antibody (Santa 
Cruz). Immune complexes were denatured and separated by SDS-PAGE gel electrophoresis. 
Gels were transferred and were individually immunoblotted with anti-p65 antibody (Santa Cruz, 
Cambridge, MA). HRP conjugates were detected with HyGlo (Denville, Metuchen, NJ) to 
determine co-immunoprecipitation reactions. Protein content was normalized using the Nano 
Photometer P-class (Implen, Westlake Village, CA) for equal loading on non-
immunoprecipitated whole cell lysates. 
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3.3.5 NF-kB p50/p65 transcription factor assay  
BV2 cells were plated at a density of 2 x 106 cells per T-75 flask. Following attachment 
cells were harvested and the nuclear proteins was prepared using the nuclear extraction kit from 
Affymetrix (AY2002) as per manufacturer’s instructions. RGS10 DNA binding activity and 
quantitation on BV2 nuclear extracts was performed by capturing NF-kB with double stranded 
oligonucleotides containing a NF-kB consensus binding site immobilized in a 96 well format 
(NF-kB p50/p65 Transcription factor assay kit, Abcam) followed by detection with RGS10 
specific and NF-kB specific antibody in a sandwich ELISA based format as per manufacturer’s 
instructions (essentially a quantitative super-shift assay).  
 
3.4 Results 
 
3.4.1 Recruitment of RGS10 and NF-κB at IL-1β and TNF-α promoter after LPS treatment 
in microglial cells 
Previous studies have shown that RGS10 is found in the nucleus of microglia, and 
downregulation of RGS10 expression promotes increased expression of IL-1β and TNF-α in 
microglial cells (Lee, Chung et al. 2011). This suggested the possibility that RGS10 may directly 
act in the nucleus to regulate transcription of these genes. To determine if RGS10 may be 
directly associated with chromatin at promoter regions of IL-1β and TNF-α, we analyzed by 
Chromatin Immunoprecipitation assay RGS10 association at IL-1β and TNF-α gene promoters. 
We designed primers and probes specific for mouse IL-1β and TNF-α gene promoters. Our data 
indicates that RGS10 was associated with IL-1β and TNF-α gene promoters in unstimulated 
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microglial cells, but this association significantly decreased following 3h and 6h of LPS 
stimulation, and was unchanged at the GAPDH control promoter (Figure 3.1A-C). 
 
RGS10 negatively regulates NF-κB in microglia and dopaminergic neurons ((Lee, 
McCoy et al. 2008)Lee et al. 2008). We next analyzed the recruitment of NF-κB to IL-1β and 
TNF-α gene promoters in unstimulated and LPS stimulated microglial cells. We observed 
significant binding of NF-κB in 6h LPS treated samples when compared to unstimulated 
microglial cells and no change in NF-κB binding at the GAPDH control promoter (Figure 3.2A-
C). In sum, we observed decreased or no binding of RGS10 at IL-1β and TNF-α gene promoters 
following 3h and 6h LPS treatment when compared to unstimulated microglial cells. In 
comparison, we observed increased binding of NF-κB following 3h and 6h of LPS treatment 
when compared to unstimulated microgial cells. These data suggest that RGS10 and NF-κB 
interact with inflammatory promoters with opposing regulation by TLR4 receptor activation in 
microglial cells. 
 
3.4.2 RGS10 protein from Nuclear extracts of Microglial cells does not directly bind to IL-1 
β promoters 
RGS10 protein has a GAP domain at its C-terminus and it has well defined NMR 
structures (Soundararajan, Willard et al. 2008). However, the N-terminus of the protein has no 
well defined structure. Our bioinformatics analysis performed using DNA binding protein 
prediction programs (DP-BIND, BINDN+) indicated that the amino acid composition in the 
RGS10 N-terminus provided for the possibility for RGS10 to bind to DNA. Arginine and serine 
residues in the N-terminus also indicated the possibility for RGS10 binding to DNA.  So next, 
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we sought to further explore the interaction of RGS10 with the promoter regions of IL-1β, by 
assessing binding of RGS10 from nuclear extracts of microglial cells with oligonucleotide 
sequences of IL-1β gene promoters using gel shift assay. Oligonucleotide sequences 
(oligonucleotide 1, oligonucleotide 2) from the IL-1β promoter were used to determine the DNA 
binding capability of RGS10 proteins from nuclear extracts of BV2 microglial cells. The 
sequences of the oligonucleotides are described in the materials and methods section. One of the 
oligonucleotide sequences, oligonucleotide 1, contains a TATA box consensus sequence and 
oligonucleotide 2 contains an NF-κB response element from mouse IL-1β promoters.  
 
A distinct gel shift with three bands was observed with nuclear extracts of microglial 
cells using oligonucleotide 2 (Figure 3.3A, Lane 5; indicated with three red arrows). The 
analysis of the results indicates Lane 1. Oligonucleotide 2 free probe observed in all the lanes 
(yellow arrow); Lane 2 shows the shift band observed with control extract; Lane 3 is the 
competition reaction where the intensity of the shift bands is decreased when compared to the 
Lane 5. Competition with unlabeled oligonucleotide 2 and labeled oligonucleotide 2 with nuclear 
extracts is a success, as indicated by the purple arrows, showing a specific interaction of nuclear 
extract with labeled oligonucleotide 2; Lane 6 is the supershift lane where the three green arrows 
indicate the bands with decreased intensity when compared to lane 5 (Figure 3.3A). We did not 
observe any bands with the same nuclear extract using oligonucleotide 1 (data not shown).  
 
In order to confirm the expression of RGS10 and NF-κB proteins in the nuclear extracts 
used for EMSA, we performed western blot analysis. Results indicate the presence of both 
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RGS10 and NF-κB  proteins in the nuclear extracts (Figure 3.3B, Lane 1 BV2 nuclear extract 
used for EMSA; Lane 2 BV2 whole cell lysate).  
 
In order to confirm if one of the bands among the three observed was specific for RGS10, 
we proceeded with supershift assays. However, no supershift was observed with RGS10 specific 
gel shift antibody (Figure 3.3A Lane 6). Instead we observed all the three bands in the same 
position as compared with shift lane, with a slight decrease in intensity of bands indicated with 
green arrows when compared to Lane 5, and also compare with Lane 8 (IgG control for 
supershift). The lack of direct binding of RGS10 to IL-1β promoter DNA suggested that the 
RGS10 protein does not associate with the oligonucleotide 2 DNA. In order to rule out the 
possibility of antibody binding to the DNA binding domain of RGS10 protein, we used both 
antibodies targeted to either the C-terminus or the N-terminus of RGS10 protein and repeated the 
supershift assay. However, once again we did not observe evidence of a supershift band. 
 
Analysis was also performed using in vitro translated recombinant human RGS10 
protein. Interestingly, recombinant RGS10 protein did not bind to oligonucleotide 2 (Figure 3.4 
compare Lane 6 and Lane 10). The analysis of the data indicates Lane 1. Oligonucleotide 2 free 
probe (Blue arrow); Lane 2. shows the shift band observed with control extract; Lane 4. is the 
competition reaction where the intensity of the shift bands is decreased when compared to the 
Lane 6 (Purple arrows) ; Lane 6. three shift bands  indicated by (Red arrows); Lane 8. 
Supershift bands observed show decrease in intensity of the bands when compared to Lane 6 
indicated by (Green arrows); Lane 9. IgG control for supershift reaction; Lane 10. In vitro 
RGS10 protein does not show interaction with oligonucleotide DNA indicated by (Black 
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arrow). Orange arrow indicates a background band observed in all the lanes. These results 
suggest that RGS10 alone has no DNA binding activity and rather that it may act as a co-
regulator/ co-factor for another transcription factor that directly binds to DNA.  
 
As an alternative approach to detect an association of RGS10 to the NF-κB response 
element, we next used a transcriptional assay using the consensus NF-κB response element 
immobilized on a 96 well plate. We assessed binding of RGS10 or NF-κB from nuclear extracts 
with both RGS10 and with NF-κB specific antibodies. There was however only minimum 
binding with NF-κB response element when compared to p50 or p65 positive controls using 
primary gel shift RGS10 and NF-κB antibodies (Figure 3.5, compare bars 3 & 4 with 7 & 8 
respectively).  Therefore, based upon these observations we could not conclude using this assay 
that RGS10 binds to the NF-κB binding site present in the oligonucleotide.  
 
3.4.3 NF-κB protein from Nuclear extracts of Microglial cells does not directly bind with 
oligonucleotide from IL-1 β promoter 
In order to confirm that the previously observed shift bands were not due to the NF-κB  
present in the nuclear extracts, we have performed gel shift assay using  double stranded DNA 
oligonucleotide 2 and BV2 nuclear extracts followed by supershift assay with NF-κB antibody. 
As previously observed, we obtained three bands with nuclear extracts of microglial cells (Figure 
3.6, lane 4). Next, we performed supershift assay using NF-κB antibody and the results indicated 
the absence of supershift band with NF-κB antibody suggesting that the oligonucleotide 2 does 
not bind NF-κB  present in BV2 nuclear extracts (Figure 3.6 lane 5; lane 6 IgG control). The blue 
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arrow pointing to the band in all the lanes is double stranded oligonucleotide 2 DNA probe and 
the orange arrow is pointing to a background band observed in all the lanes.  
 
3.4.4 RGS10 does not co-immunoprecipitate with the p65 subunit of NF-κB  
To further investigate the molecular mechanism by which RGS10 is promoting its anti-
inflammatory activity, we considered that RGS10 might be interacting with NF-κB and 
negatively regulating NF-κB signaling pathways. So, we next sought to determine if RGS10 
associates with the p65 subunit of NF-κB and promotes negative regulation of NF-κB. 
Microglial cells were either untreated or were treated with LPS (10µM) for 3hrs and the lysates 
were analyzed by co-immunoprecipitation assay to verify interactions between RGS10 and the 
p65 subunit of NF-κB. Our observations indicate no association between RGS10 and the p65 
subunit of NF-κB in untreated microglial cells (Figure 3.7A compare lane 1 (positive control) 
and lane 3 (experimental sample) and Figure 3.7B shows lack of association in LPS treated 
microglial cells  (compare lane 1 (positive control) and lane 3 (experimental sample). Lysate 
blots show the presence of both RGS10 and NF-κB in cell lysates. 
 
3.5 Discussion 
A better understanding of how RGS10 protein in microglial cells modulates 
inflammatory cytokine production such as IL-1β, TNF-α under LPS stimulation  will extend the 
usage of RGS10 as a therapeutic target for regulating neuroinflammatory conditions in the CNS. 
In this study, we investigated the molecular mechanisms by which RGS10 protein regulates 
inflammatory cytokine gene expression in response to LPS in microglial cells. We identify that 
LPS treatment decreases RGS10 binding to IL-1β and TNF-α promoters and further demonstrate 
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an increase in NF-κB binding to these promoters in the BV2 microglial cell line. IL-1β and TNF-
α are potent proinflammatory cytokines that promote inflammation in CNS. Our data indicate 
that with LPS treatment, there is decreased binding of RGS10 at IL-1β and TNF-α promoters 
and, correspondingly, there is increased binding of NF-κB. 
 
Palmitoylation at Cysteine 66 markedly targets RGS10 to localize to the membrane and 
increases its GAP activity (Tu, Popov et al. 1999). The N-terminus of RGS10 contains sequences 
enriched in proline, glutamic acid, serine and threonine. The N-terminus of RGS10 protein 
sequence remains unstructured and the C-terminus is the RGS domain (Popov, Yu et al. 1997) 
(Hunt, Fields et al. 1996). RGS10 is regulated by cAMP-dependent protein kinase A (PKA) 
phosphorylation on Serine 186 on KRAS motif in its C-terminus (Burgon, Lee et al. 2001). 
Phosphorylation of RGS10 promotes translocation of RGS10 from the cytosol to the nucleus. 
The nuclear roles of RGS10 remain unclear because most G-protein coupled receptors are 
localized to plasma membranes. The canonical function of RGS10 protein is that it inhibits 
GPCR signaling by acting as a GTPase activating protein (GAP) and converts GTP to GDP 
resulting in downregulation of GPCR signaling (Ross and Wilkie 2000) (Sierra, Gilbert et al. 
2002).  
 
Based on our observations from ChIP assays, which indicated RGS10 binding at IL-1beta 
and TNF-alpha promoters, we wanted to further investigate if RGS10 is directly binding to these 
gene promoters and further regulating them (Figure 3.1). In order to determine these possibilities, 
we performed gel shift assays to determine associations of RGS10 with promoter regions of IL-
1beta genes. For the assay, we designed double stranded oligonucleotide DNA spanning the IL-
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1beta promoter, region spanning the primers and probe region used for the ChIP assay. The 
analysis was carried out with two oligonucleotides, oligonucleotide 1 contained a TATA box 
sequence and oligonucleotide 2 contained NF-κB consensus binding sites. The purpose of 
including the NF-κB binding site in oligonucleotide 2 was that there was a possibility for RGS10 
in the nuclear extracts of microglial cells to bind to the NF-kB site and negatively regulate NF-
κB signaling in these cells. However, there was no direct association of RGS10 with either of 
these oligonucleotides (Figures 3.3 & 3.4). As we continue this work, one possibility will be to 
continue this analysis with more oligonucleotides spanning the IL-1beta primers used for the 
ChIP assay. 
  
An alternative approach to detect an association of RGS10 to the NF-κB response 
element, we used NF-κB transcription factor assay.  However, there was minimum binding of 
NF-κB and RGS10 to the NF-κB binding site on the oligonucleotide (Figure 3.5). This result 
indicated that RGS10 does not directly bind to the NF-κB binding site on the oligonucleotide. 
We next analyzed whether there was any interaction between RGS10 and the p65 subunit of NF-
κB. This step would help us to identify whether RGS10 regulates NF-κB under LPS stimulation.  
Our results indicate there is no direct association between RGS10 and NF-κB (Figure 3.7)  
 
Together our findings contribute significantly to understanding the non-canonical role of 
RGS10 in regulating proinflammatory cytokine genes. Our study reveals an unexpected 
association of RGS10 associates with promoter regions of proinflammatory cytokines such as IL-
1β and TNF-α, providing a novel mechanism for RGS protein effects. While our results fail to 
identify the mechanism by which RGS10 assocaites with chromatin and regulates expression of 
pro-inflammatory genes, several lines of ongoing work will continue to pursue this goal. 
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Specifically, through collaboration with the Hooks lab at the university of Georgia, we are 
pursuing the hypothesis that the relevant target of RGS10 association with IL-1βand TNF-α is 
mediated by the Cyclic AMP response element (CRE), found in these promoters upstream of the 
NF-κB site. We are also pursuing broad unbiased approaches to identify both novel RGS10 
nuclear protein binding partners and novel DNA targets of RGS10 association in microglia. 
These approaches and their rationale are discussed in further detail below.  
 
It has been shown that RGS10 promotes neuroprotection to dopaminergic neurons 
through the phospho cyclic-AMP response element binding signaling pathway (Lee, Chung et al. 
2012).  Overexpression of RGS10 in MN9D cells treated with TNF-alpha showed higher levels 
of phosho-CREB and CREB protein levels when compared to TNF-alpha treated parental MN9D 
and MN9D cells overexpressing mutant RGS10 protein (RGS10SA). Consistent with phospho 
CREB and CREB protein levels in RGS10 overexpressed MN9D cells, there was 
correspondingly significant increase in pro-survival bcl-2 protein, thus promoting its 
neuroprotective effect on DA neurons. Based on these observations, we considered that RGS10 
might be following the CREB signaling pathway in microglial cells to promote it’s anti-
inflammatory properties.  It has been shown that CREB is bound to the CRE site upstream of NF-
κB in basal microglia, and that this association is lost following activation, consistent with the 
patterm of RGS10 association. Further, CREB and NF-κB have been shown to compete for 
limiting amounts of CBP with is necessary for activation, so that CREB can directly oppose NF-
κB transcriptional activity. Finally, a preliminary RGS10 co-IP and MS analysis of interacting 
proteins suggested association of RGS10 with both CREB and CBP, indicating this is a 
promising direction to investigate in nuclear RGS10 function in microglial cells. Our future 
collaborative studies with the Hooks lab will focus on investigating the molecular mechanisms 
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by which RGS10 associates with CREB using co-immunoprecipitation and gel shift assays with 
oligonucleotide DNA containing consensus CREB binding sequences.   
   
While we are pursuing a possible interaction with RGS10 and CREB proteins, we also 
propose that RGS10 may interact with multiple additional protein and DNA targets in microglia 
nuclei. Indeed, our preliminary MS analysis identified multiple additional nuclear RGS10 
binding partners, including transcription factors. Further analysis by Immunoprecipitation of 
nuclear extracts using RGS10 antibody followed by mass spectrometry will help identify the 
molecules that associate with RGS10. The identification of transcription factors will further help 
in delineating the ability of RGS10 to bind DNA. The identified molecules will also help in 
investigating the mechanism by which RGS10 negatively regulates NF-κB signaling under LPS 
stimulation and thereby promotes its anti-inflammatory properties.  Finally, our ChIP studies 
focused only on two potential promoter regions. We hypothesize that RGS10 may interact with 
multiple DNA targets. To pursue this possibility, we plan to perform next generation deep 
sequencing of DNA associated with RGS10 following  chromatin IP (ChIP-seq) to fully identify 
the DNA sequences targeted by RGS10 association. 
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Figure 3.1 Association of RGS10 at IL-1β and TNF-α promoters in BV2 microglial cells 
ChIP assays were carried out in BV2 microglial cells. Cell Lysates were immunoprecipitated 
with control (mouse IgG), and anti-RGS10 antibody. Associated DNA was isolated and analyzed 
via real time PCR using primers and probe spanning the IL-1β, TNF-α and GAPDH promoters. 
Real-time PCR values were normalized to the total amount of promoter DNA added (input). 
Input values represent 5% of the total cell lysate. * p<0.05. A. RGS10 associated with IL-1β 
promoter in microglial cells and B. RGS10 associated with TNF-α promoter in microglial cells 
C. RGS10 binding at GAPDH promoter in microglial cells. Values represent mean ± SEM of 
four independent experiments. 
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Figure 3.2 Association of NF-κB at IL-1β and TNF-α promoters in BV2 microglial cells 
ChIP assays were carried out in BV2 microglial cells. Cell lysates were immunoprecipitated with 
control (mouse IgG) and NF-κB antibody. Associated DNA was isolated and analyzed via real 
time PCR using primers and probe spanning the IL-1β, TNF-α and GAPDH promoters. Real-
time PCR values were normalized to the total amount of promoter DNA added (input). Input 
values represent 5% of the total cell lysate. * p<0.05. A. NF-κB associated with IL-1β promoter 
in microglial cells and B. NF-κB associated with TNF-α promoter in microglial cells C. NF-κB 
binding at GAPDH promoter in microglial cells. Values represent mean ± SEM of four 
independent experiments.  
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Figure 3.3 RGS10 does not directly bind at IL-1β promoter in BV2 microglial cells 
(A.) EMSA with biotin labeled oligonucleotide having NF-κB consensus DNA binding response 
element with nuclear extracts from BV2 cells. Nuclear extracts from HeLa cells provided in the 
kit, were used as positive control and oligonucleotide alone was used as negative control. Excess 
unlabeled oligonucleotide containing NF-κB response element was used to monitor non-specific 
binding. Lane 1. Double stranded Oligonucleotide 2; Lane 2. Control Nuclear Extract and 
Control Probe from kit; Lane 3. Competition reaction with Unlabeled-Oligonucleotide 2, 
Labeled-Oligonucleotide 2 and Nuclear extract .The intensity of the Shift bands is decreased 
indicated by Purple arrows when compared to Lane 5 (Shift reaction indicated by Red arrows); 
Lane 5. Three bands are the shift bands indicated by (Red arrows) (Oligonucleotide 2 + BV2 
cells Nuclear Extract); Lane 6 Supershift reaction (Oligonucleotide2 + Nuclear extract + RGS10 
antibody) (Green arrows) Lane 8. Supershift IgG Control (Oligonucleotide2 + Nuclear Extract + 
IgG antibody). Yellow arrow indicates the double stranded oligonucleotide 2 observed in all the 
lanes. Experiment shown is representative of five experimental repeats. 
(B.) Lysates were normalized for protein concentration, and were separated on 10% SDS-PAGE 
gels by electrophoresis. Blots were individually immunoblotted with anti-p65 NF-κB subunit and 
RGS10 antibodies (Santa Cruz). HRP conjugates were detected with Denville Hyglo 
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Figure 3.4 In vitro RGS10 does not directly bind at IL-1β promoter in BV2 microglial cells 
EMSA with biotin labeled oligonucleotide having NF-κB consensus DNA binding response 
element with nuclear extracts from BV2 cells. Nuclear extracts from HeLa cells provided in the 
kit, were used as positive control and oligonucleotide alone was used as negative control. Excess 
unlabeled oligonucleotide 2 was used to monitor non-specific binding. Lane 1. Oligonucleotide 2 
Free Probe (Blue arrow); Lane 2. Control Nuclear Extract and Control Probe from kit; Lane 4. 
Competition with Unlabeled-Oligonucleotide2 and Labeled-Oligonucleotide2 (Purple arrows) ; 
Lane 6. Oligonucleotide 2 + BV2 Nuclear Extract (Shift bands indicated by Red arrows); Lane 8. 
Oligonucleotide 2 + Nuclear Extract + RGS10 antibody (Supershift bands indicated with Green 
arrows); Lane 9. Oligonucleotide 2 + Nuclear Extract + IgG antibody; Lane 10. Oligonucleotide 
2 + In vitro RGS10 protein (Shift bands not observed indicated by Black arrow). Orange arrow 
indicates a background band observed in all the lanes. Experiment shown is representative of two 
experimental repeats. 
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Figure 3.5 RGS10 and NF-κB binding in sandwich based ELISA system 
RGS10 and NF-κB binding was captured by double stranded oligonucleotide with NF-κB DNA 
binding response element immobilized on a 96 well plate. The captured RGS10 and NF-κB was 
detected using RGS10, NF-κB antibodies respectively followed by measuring the intensity at 
450 nm using HRP coupled secondary antibody.  The data from three independent experiments 
in triplicate is expressed as mean  ±  SEM. 
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Figure 3.6 NF-κB  does not directly bind at IL-1β promoter in BV2 microglial cells 
EMSA with biotin labeled oligonucleotide 2 with nuclear extracts from BV2 cells. Nuclear 
extracts from HeLa cells provided in the kit, were used as positive control and oligonucleotide 
alone was used as negative control. Excess unlabeled oligonucleotide 2 was used to monitor non-
specific binding. Lane 1. Oligonucleotide 2 Free Probe (Blue arrow); Lane 2. Control Nuclear 
Extract and Control Probe from kit; Lane 3. Competition with Unlabeled-Oligonucleotide 2 and 
Labeled-Oligonucleotide 2 (Purple arrows); Lane 4. Oligonucleotide 2 + BV2 Nuclear Extract 
(Shift bands indicated by Red arrows); Lane 5. Oligonucleotide 2 + Nuclear Extract + NF-κB 
antibody (Green arrows); Lane 6. Oligonucleotide 2 + Nuclear Extract + IgG antibody (Black 
arrows); Lane 7. NF-κB antibody alone. Orange arrow indicates a background band observed in 
all the lanes. Experiment shown is representative of two experimental repeats. 
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Figure 3.7 RGS10 does not associate with the p65 NF-κB 
(A.) Co-immunoprecipitation of RGS10 and p65 NF-κB : BV2 Cells were harvested, lysed, pre-
cleared and immunoprecipitated (IP) with anti-RGS10 and anti- Mouse IgG. Western blots were 
performed and Immunoprecipitated samples were immunoblotted (IB) using NF-κB antibody. 
Lysate controls demonstrate expression of RGS10 and NF-κB. Data shown are representative of 
two individual experiments. Lane 1 Positive Control: Immunoprecipitation with NF-κB and Blot 
for NF-κB; Lane 2 Negative Control: IgG; Lane 3 Experimental Immunoprecipitation with 
RGS10 and Blot for NF-κB. IP samples (top panel) and lysates (bottom panels) were 
Immunoblotted with NF-κB and RGS10 as indicated. Results shown are indicative of data from 
two biologically independent experiments. 
(B.) Co-immunoprecipitation of RGS10 and p65 NF-κB in 3 hr LPS treated BV2 cells: BV2 
Cells were treated with 3 hr LPS harvested, lysed, pre-cleared and immunoprecipitated (IP) with 
anti-NF-κB  and anti- Mouse IgG. Western blots were performed and Immunoprecipitated 
samples were immunoblotted (IB) using RGS10 antibody. Lysate controls demonstrate 
expression of RGS10 and NF-κB. Data shown are representative of two individual experiments. 
Lane 1 Positive Control: Immunoprecipitation with RGS10 and Blot for RGS10; Lane 2 
Negative Control: IgG; Lane 3 Experimental Immunoprecipitation with NF-κB and Blot for 
RGS10. IP samples (top panel) and lysates (bottom panels) were Immunoblotted with RGS10 
and NF-κB as indicated. Results shown are indicative of data from two biologically independent 
experiments. 
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4 CHAPTER IV: CONCLUSIONS 
 
Transcription of genes in all living organisms involves the interplay of transcription 
factor complexes which are recruited to the promoters of genes and help to generate 
macromolecules for life. Gene expression is regulated at several steps including initiation, 
elongation, and termination of transcription. The 26S proteasome has the ability to degrade 
polyubiquitinated proteins and also plays a critical role as transcriptional regulator of genes 
(Kwak, Workman et al. 2011). The 26S proteasome consists of two subunits, a 19S regulatory 
particle and 20S proteolytic core. The 19S ATPases, subunits of the 19S regulatory particle, are 
known to play roles in unfolding of polyubiquitinated proteins and to direct proteins towards the 
20S core for protein degradation (Coux, Tanaka et al. 1996) (Glickman, Rubin et al. 1999). 
When we began our work, it had recently been shown that the 19S ATPases could separate from 
the 19S regulatory particle subunit and associate with inducible promoters in order to regulate 
transcription of yeast genes (Ferdous, Gonzalez et al. 2001) (Ferdous, Kodadek et al. 2002) 
(Gonzalez, Delahodde et al. 2002) (Lee, Ezhkova et al. 2005). In mammalian systems, 
interactions of 19S ATPases had also been shown with glucocorticoid receptors, retinoic acid 
receptors, with the HIV- Tat promoter region, and with tumor suppressor p53 genes (Ferdous, 
Kodadek et al. 2002) (Zhu, Wani et al. 2007) (Lassot, Latreille et al. 2007) (Kinyamu, Chen et al. 
2005). However, the mechanism by which 19S ATPases regulate mammalian transcription 
remained unknown. 
Major histocompatibility complex molecules (MHCII) are cell surface glycoproteins that 
present extracellular antigens to CD4+ T lymphocytes in order to initiate the adaptive immune 
response. MHCII proteins play important roles in activating immune responses to foreign 
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invaders, however overexpression of MHCII also contributes to autoimmune disorders (Walter, 
Lingnau et al. 2000) (Warabi, Kitagawa et al. 2000) (Simon and Lange 2008). During the 
inflammatory response to Multiple Sclerosis, T cells are sensitized against myelin components in 
the central nervous system via MHCII expression of myelin peptides. The sensitized T cells enter 
the CNS and are activated by resident antigen-presenting cells, resulting in a cascade of 
inflammatory damage. Neuroinflammation promotes accumulation of soluble mediators such as 
TNF-α, IL-1, and IL-6 that cause neuronal cell damage or death (Hauser and Oksenberg 2006) 
(Owens 2003) (Benveniste 1997) (Jack, Ruffini et al. 2005) (Czeh, Gressens et al. 2011). The 
initial inflammatory phase is followed by demyelination and finally neurodegeneration (Owens 
2003) (Frischer, Bramow et al. 2009) (Hauser and Oksenberg 2006). One way to aid in the 
treatment for multiple sclerosis is through better understanding of MHCII gene transcription with 
the possibility that enhancing our ability to manipulate MHCII gene expression will allow 
specific reduction of neuroinflammation in the CNS. 
The Class II transactivator is the master regulator of MHCII genes, and is required to be 
present at the MHCII promoter in order to drive MHCII transcription (Beresford and Boss 2001) 
(Ting and Trowsdale 2002) (Drozina, Kohoutek et al. 2006). The levels of expression of CIITA 
are therefore tightly regulated (Gerloni and Zanetti 2005) (Kaufman, Auffray et al. 1984) 
(Masternak, Muhlethaler-Mottet et al. 2000) (Mach, Steimle et al. 1996). CIITA transcription is 
driven by four distinct promoters I, II, III, IV and specific isoform expression is determined by 
the type of cells in which CIITA is found and the cytokine that stimulates CIITA production. 
This dissertation focuses on CIITApIV, which is expressed in IFN-γ induced nucleated cells 
(Muhlethaler-Mottet, Otten et al. 1997). Understanding CIITA regulation will lead to a greater 
ability to manipulate MHCII expression.  
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Our lab has shown that 19S ATPases (Sug1 and S6a) of 26S proteasome play an 
important role in the transcription initiation of CIITA expression (Bhat, Turner et al. 2008) 
(Truax, Koues et al. 2010). However, the roles of 19S ATPases in transcription elongation 
remains to be identified. Recently, it has been found in yeast that 19S ATPases play important 
roles in RNA pol II dependent elongation (Ferdous, Gonzalez et al. 2001). We focused here on 
determining the impact of 19S ATPases on IFN-gamma induced CIITApIV gene transcription. 
In order to understand functional involvement of 19S proteasome in gene expression, we 
have investigated the role of 19S ATPases Sug1, S7 and S6a in regulating transcription 
elongation of CIITA. We choose CIITA for our analysis because as the master regulator of 
MHCII genes, CIITA is a critical AND inducible gene (Wang 2003). Our lab has observed that 
the 19S ATPase Sug1 plays important roles in regulating transcription initiation of MHCII genes 
and that a lack of Sug1 showed decreased recruitment of CIITA to MHCII promoters (Bhat, 
Turner et al. 2008). Further, Sug1 was shown to regulate histone modifications of MHCII genes, 
indicating the ability of 19S ATPases to regulate epigenetic modifications (Koues, Dudley et al. 
2008) (Koues, Dudley et al. 2009). However, the full role of 19S ATPases in regulating 
transcription of CIITA remained to be explored.  
 To begin our investigation, we focused on depletion of 19S ATPases Sug1, S7, 
S6a by siRNA mediated knockdown and observed the generation of CIITApIV transcripts 
(Maganti, Moody et al. 2014). Our observations indicate that lack of 19S ATPases significantly 
decreased the generation of longer CIITApIV transcripts. We next investigated the effect of 
proteasome inhibitors on CIITApIV transcription. Evidence previously generated in yeast 
systems indicates that the 19S subunit of the 26S proteasome has the ability to function 
independently of the 20S catalytic core (Ferdous, Gonzalez et al. 2001). Our data also indicates 
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that inhibition of proteasome activity increases transcription of CIITApIV while knockdown of 
19S ATPases decreases transcription of CIITApIV. These data support that 19S ATPases are 
essential for transcription elongation of CIITApIV.  
It is known that specific phosphorylations of RNA pol II C-terminal domain are required 
for both transcription initiation and elongation (Sims, Belotserkovskaya et al. 2004) (Hager, 
McNally et al. 2009). Serine 5 of RNA pol II CTD has to be phosphorylated is required for the 
transition from initiation to elongation whereas Serine 2 phosphorylation is required for 
elongation (Hager, McNally et al. 2009). Phosphorylation of these Serine residues is mediated by 
Cyclin-dependent kinase7 (CDK7) and Cyclin-dependent kinase9 (CDK9). CDK7 is a 
component of transcription factor TFIIH which promotes Serine 5  phosphorylation, CDK9 is a 
component of transcription elongation factor PTEF-b which promotes Serine 2 phosphorylation   
(Hager, McNally et al. 2009). RNA pol II promoter escape from promoter to the coding region is 
highly regulated by these phosphorylation events at RNA pol II CTD.  Therefore, we next sought 
to determine if 19S ATPases associate with phosphorylated forms of RNA pol II, which are 
required for transcription. Our data indicates that 19S ATPases Sug1, S7, S6a associate with 
Ser5 phosphorylated RNA pol II which is required for transition from initiation to elongation. 
We further noted that siRNA mediated knockdown of 19S ATPases has no impact on the RNA 
pol II levels in cell lysates, but has varied effects on phosphorylated forms of RNA pol II. There 
is decrease in Ser5 phosphorylated RNA pol II and in the case of Ser2 phosphorylated RNA pol 
II S7 knockdown samples have less negative impact when compared to Sug1 and S6a 
knockdown samples. This data suggests that 19S ATPases play a role in transcription initiation 
and also in transition to productive elongation phase.  
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RNA pol II pauses after synthesis of approximately 50 bases of RNA due to action of 
negative elongation factor (NELF) and DRB sensitivity inducing factor (DSIF) (Saunders, Core 
et al. 2006). RNA pol II pausing is overcome by recruitment of CDK9 which phosphorylates 
NELF and DSIF as well as Serine 2 at RNA pol II CTD repeats. These phosphorylations 
promote productive elongation, mRNA synthesis, transcriptional termination, and chromatin 
modifications (Saunders, Core et al. 2006). 
Association of 19S ATPases with PTEFb components indicates their role in transcription 
elongation complex assembly. Studies in yeast demonstrate that 19S proteasome components 
associate with actively transcribing genes and facilitate recruitment of various transcription 
factors (Ferdous, Gonzalez et al. 2001). PTEFb is recruited to an early elongation complex on the 
HIV long term repeats and form a complex with Tat trans-activator protein (Zhou, Chen et al. 
1998) (Kanazawa, Okamoto et al. 2000). CIITA recruits PTEFb containing cyclin T1 to MHCII 
gene promoter (Kohoutek, Blazek et al. 2006). Upon stimulation, PTEFb dissociates from large 
inactive complex and forms small complex that is recruited to transcriptional machinery (Yang, 
Zhu et al. 2001). PTEFb exists in both inactive and active forms, where the inactive form is 
bound to Hexim-1 and 7SK RNA. Based on the association of 19S ATPases with coding regions 
of CIITApIV, our next question was to determine whether 19S ATPases interact with positive 
transcription elongation factor PTEFb. Our observations indicate that Sug1, S7, and S6a interact 
with PTEFb components Hexim1 and CDK9. When PTEF-b is bound to Hexim1 and 7SK RNA, 
it is inactive and when it is bound to CDK9 it is active.  The association of 19S ATPases Sug1, 
S7, S6a with Hexim-1 and with CDK9 indicate their role in promoting the switch from the 
inactive to the active form of PTEFb.  
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Our next question was to determine if Sug1, S7, and S6a play a role in maintaining 
transcription, so we knocked down Sug1, S7 and S6a using ATPase specific siRNA and 
observed that levels of RNA pol II and TATA binding protein (TBP) are significantly reduced at 
CIITApIV promoters. In addition, co-immunoprecipitations indicated Sug1, S7 and S6a all 
associate with Hexim-1 and CDK9 components of the PTEF-b complex. Further, Proteasome 
inhibition via MG132 or Lactacystin treatment does not impact transcript generation from 
CIITApIV. These observations indicated that 19S ATPases play a very important role in 
regulating CIITA transcription by indicating independent function of 19S proteasomal subunits 
and 20S core in regulating gene transcription. (Peters, Franke et al. 1994) (Sikder, Johnston et al. 
2006). Together, our findings suggest that 19S ATPases are involved in both transcription 
initiation and in elongation of CIITApIV genes (Figure 4.1). 
In sum, we demonstrate that 19S ATPases regulate transcription elongation of cytokine 
inducible CIITA mammalian genes. We show subunits of the 19S proteasome; Sug1, S7, S6a are 
important players in transcriptional processes, as they regulate expression of CIITA at the levels 
of both transcription initiation and elongation. Based on the work in this dissertation, these 
findings advance our knowledge of the functions of the 26S proteasome in regulating 
transcription of CIITA genes. The molecular mechanisms supporting this regulation remain 
unknown. While the transcription factors required for elongation have been determined, 
limitations of methodogy have hampered our ability to determine the sequence of recruitment of 
factors for efficient transcription. 
 
Full determination of the involvement of 19S proteasomal subunits in transcription 
termination will enable elucidation of a more complete understanding of the transcription 
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process, in order that we can efficiently regulate the expression of CIITA in MHCII defective 
diseases. The structure of chromatin plays critical roles in regulating transcription elongation. 
The yeast 19S ATPases Rpt6 (hSug1) and Rpt4 (hS10b) promote H3 methylation modifications 
and regulate transcription (Ezhkova and Tansey 2004). Future work will focus on understanding 
the role of 19S ATPases in regulating transcription elongation by controlling epigenetic 
modifications and by recruiting chromatin remodeling enzymes such as chromodomain helicase 
DNA-binding 1 (CHD1) to promote chromatin accessibility for RNA Pol II to proceed along the 
coding region of transcribing genes and regulate transcription elongation. Future investigations 
will address roles of 19S ATPases in maintaining acetylation levels on Histone H3 and H4 and 
methylation on Histone H3 at K36 on actively transcribing genes (Pokholok, Harbison et al. 
2005) (Liu, Kaplan et al. 2005).  
 
As CIITA is the master regulator for MHCII genes and is essential for MHCII gene 
expression, in order to maintain tight regulation of MHCII, CIITA expression is also tightly 
regulated at the level of transcription (Ting and Trowsdale 2002). The regulation of inducible 
form of CIITApIV results in parallel induction of inducible expression of MHCII (Muhlethaler-
Mottet, Otten et al. 1997) (Morris, Beresford et al. 2002), it is critical that CIITA expression is 
tightly regulated because abberant expression of MHCII is associated with autoimmune disorders 
such as Multiple Sclerosis. According to Multiple Sclerosis society more than 2.1 million 
individuals in the United States suffer with this disease which affects about 6% of the population 
and is the third largest disease burden in US after heart disease and cancer (Siatskas, Chan et al. 
2006) (Swanberg, Lidman et al. 2005). One way to suppress inflammation in autoimmune 
disorders such as Multiple Sclerosis is by regulating MHCII gene expression. Therefore, gaining 
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better insights to the transcription regulation of CIITApIV gene will enhance the development of 
therapeutic strategies for the treatment of MHCII defective diseases such as autoimmune 
diseases and inflammation. 
 
An additional mechanism to suppress neuroinflammation is via regulation of the 
expression of the Regulator of G-protein signaling 10 (RGS10) genes in resident CNS microglial 
cells. Inflammation of the central nervous system is initiated by infection, brain injury, release of 
toxic metabolites, or autoimmunity to brain tissue which activates microglial cells. Sustained 
activation of microglial cells leads to the recruitment of other immune cells to the brain tissues, 
causing neurodegenerative conditions in the CNS. Inflammation in the case of Multiple Sclerosis 
causes demylination of nerve fibers, leading to neuronal dysfunction and, in the case of 
neurodegenerative diseases such as Alzheimer’s and Parkinson’s, causes damage to the neurons.  
Recent evidence suggests that resident macrophages in the CNS (microglial cells) express high 
levels of RGS10 in order to promote homeostasis in the CNS. However, chronic activation of 
microglial cells leads to the release of cytokines such as TNF-α and IL-1β which in turn cause 
neuroinflammation. Microglia are known to be involved in the initiation and progression of 
neurodegenerative diseases such as Multiple Sclerosis, Alzheimers, and Parkinsons disease (Fu, 
Shen et al. 2014) (Tansey, McCoy et al. 2007). Alzheimer’s and Parkinson’s are the most 
common neurodegenerative disorders affecting individuals over 65 years of age. An estimate of 
5.3 million Americans suffer from Alzheimer’s and this disease is the sixth leading cause of 
death in the United States (Alzheimer's 2015). In the case of Parkinson’s disease, about 3% of 
the individuals between the ages of 65 to 80 are affected by this disease (National Institute of 
Neurological Disorders and Stroke 2013). Overall these chronic neurological disorders affect 
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millions of individuals in the United States and worldwide. As such, greater understanding of the 
regulation of microglia mediated neuroinflammation will enhance our ability to treat these 
diseases.  
 
The Tansey group has made the critical observation that the RGS10 protein is a regulator 
of proinflammatory cytokine production and serves as a neuroprotective factor in microglia (Lee, 
McCoy et al. 2008) (Lee, Chung et al. 2011). Microglia are brain resident macrophages in the 
CNS and RGS10 is abundantly expressed in these cells.  Microglial cells are responsible for 
maintaining homeostatic conditions in the CNS by clearing damaged and/or infected cells in the 
CNS (Domercq, Vazquez-Villoldo et al. 2013) (Streit 2000). On the other hand, over activation 
of microglial cells leads to production of proinflammatory cytokines, reactive oxygen species, 
and promotes neurotoxic effects in the CNS (Block, Zecca et al. 2007). Therefore studying the 
regulation of microglial cells will aid in identification of molecular targets for treating 
neuroinflammatory conditions in the CNS. Accumulating evidence shows that RGS10 plays 
critical role in regulating microglial activation in the brain (Waugh, Lou et al. 2005). However, 
the mechanisms by which RGS10 promotes anti-inflammatory signaling has not been defined in 
microglial cells.  
 
Microglia express multiple receptor types including Toll-like receptors which are 
activated by LPS and G-protein coupled receptors (GPCR’s) which are activated by various 
endogenous signaling molecules (Kielian 2006). Activation of these receptors by different 
ligands results in tight regulation of inflammatory cytokines including TNF-alpha and IL-1 beta. 
The ability of RGS10 to regulate NF-κB signaling pathway stimulated by LPS, leading to 
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inflammatory cytokine production in BV2 cells has been demonstrated by the Tansey research 
group (Lee, McCoy et al. 2008) (Lee, Chung et al. 2011). However, the mechanisms by which 
RGS10 controls TLR-mediated pathway has not been fully explored. Thus understanding how 
RGS10 can regulate TLR4 mediated NF-κB signaling in LPS treated microglial cells will help us 
identify therapeutic targets for treating neuroinflammation in the CNS.  
In order to investigate LPS-induced cytokine production in BV2 cells, we first 
determined binding of RGS10 to IL-1beta gene promoters. We found through ChIP assays that 
RGS10 associates with IL-1beta and TNF-alpha genes in untreated microglial cells when 
compared to LPS treated microglial cells. Based on this evidence from ChIP assay results, we 
focused on the promoter region of IL-1beta gene where we designed primers used for the ChIP 
assay. We designed two oligonucleotides spanning this region, one oligonucleotide contained 
TATAA binding element and the other oligonucleotide contained the NF-κB binding element. 
We investigated binding of RGS10 to the above designed oligonucleotides by gel shift assay, but 
the analysis failed to identify direct binding between RGS10 and the oligonucleotides. These 
data suggest that RGS10 does not bind to the DNA directly, but may act as a co-factor to another 
transcription factor that directly binds DNA.  
Our next approach could be to design additional oligonucleotides from the IL-1beta 
promoter region specifically including the region between the primers used for the ChIP assay 
and then perform EMSAs. Alternatively, it is well known that the interaction between protein 
subunits, or between two proteins, plays an important role in binding to DNA (Hai and Curran 
1991) (Mohana-Borges, Pacheco et al. 2000). Therefore, RGS10 might be associating with 
another protein from the nuclear extract and forming a heterodimer or a homodimer that can bind 
to DNA.  
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Thus, we considered that another way to show the interaction of RGS10 with DNA 
would be to use a transcription factor assay, which is quite sensitive and would enable 
determination of the binding of RGS10 to NF-κB consensus sequence on the oligonucleotide 
(Knowell, Patel et al. 2013). Our data suggested that there was minimum binding with the 
oligonucleotide containing consensus NF-κB binding site coated on the plate for both RGS10 
and NF-κB, indicating that RGS10 does not bind to the NF-κB consensus sequence in the 
oligonucleotide. This data suggests that RGS10 might be competing with NF-κB for binding to 
the NF-κB consensus binding element in unstimulated microglial cells and negatively regulating 
NF-κB signaling pathways.  
We next sought to determine whether there was interaction between RGS10 and p65 NF-
κB subunit in LPS treated BV2 samples by using co-immunoprecipitation. These data indicate 
there was no interaction between the two proteins. Based on the evidence from the Tansey 
research group that neuroprotective effects of RGS10 in neurons require its nuclear localization 
(Lee, McCoy et al. 2008), further studies are required to identify binding partners of RGS10 in 
the nucleus which promote its nuclear function in microglia. 
Our findings bring to light questions regarding the role of RGS10 in regulating 
neuroinflammation in the CNS. We show that RGS10 associates with promoter regions of 
proinflammatory cytokine genes such as IL-1beta and TNF-alpha and indicate exciting 
preliminary roles for RGS10 in regulating these genes. But we could not identify the mechanism 
by which RGS10 promotes its anti-inflammatory property. Based on the work in this 
dissertation, these findings advance our knowledge of the role of RGS10 in regulating 
chronically activated microglial cells. Future work will focus on the identification of molecules 
that associate with nuclear RGS10 in microglial cells. Further investigations will attempt to 
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identify transcription factors which might assist RGS10 in its ability to bind to DNA and further 
advance our knowledge in investigating the pathway through which RGS10 promotes its anti-
inflammatory activity.  
There is evidence that RGS10 promotes neuroprotection to dopaminergic neurons 
through the cyclic-AMP response element binding signaling pathway (Lee, Chung et al. 2012). 
Therefore, future work will also address the molecular mechanisms by which RGS10 is 
promoting it’s anti-inflammatory activity through CREB signaling pathway (Figure 4.2). 
Understanding the mechanisms by which RGS10 reduces pro-inflammatory cytokine production 
in microglia could help in the design of novel therapeutic targets for nueroinflammatory diseases 
that are associated with excessive microglial activation. Novel ways of restoring RGS10 protein 
levels in activated microglia could help treat neuroinflammation, a characteristic feature of 
neurodegenerative diseases. 
In sum, our observations are two -fold: first, we increase the understanding of the role of 
the Ubiquitin proteasome system in modulating CIITA mediated MHC class II transcription and 
thus facilitate the development of novel therapies involving manipulation of MHC class II gene 
expression in autoimmune diseases. Second, by studying the role of RGS10 in regulating 
proinflammatory cytokine release by microglial cells, we provide additional targets to combat 
neuroinflammation in Multiple Sclerosis and also in other neurodegenerative diseases such as 
Alzheimer’s and Parkinson’s (Figure 4.3). 
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Figure 4.1 Transcription regulation of CIITApIV gene 
IFN-γ stimulation activates JAK STAT signaling pathway and results in the recruitment of 
transcription factors and histone modifying enzymes, which, along with the actions of 19S 
ATPases, are crucial in mediating transcriptional initiation of CIITApIV gene and also Shortly 
after the transcription start site, the polymerase pauses; IFN-gamma stimulation also 
promotes19S ATPases to associate with both active and inactive form of PTEF-b and aid in 
promoting the switch from an inactive to active elongation complex. Activated PTEF-b is 
recruited to the CIITApIV promoter and phosphorylates serine 2 on the CTD of RNA 
polymerase II to initiate mRNA synthesis and the release of the polymerase is mediated by a 
series of phosphorylation events involving DSIF and NTEF which initiates productive 
elongation. 
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Figure 4.2 Model for mechanism by which RGS10 regulates chronically activated 
microglial cells 
We could not identify the association of RGS10 anti-inflammatory activity to NF-κB signaling 
pathway in LPS treated microglial cells . Based on observation of Tansey group in Dopaminergic 
neurons, the probable model under investigation would be interaction of RGS10 with PKA might 
promote survival signaling and by attenuating caspase dependent apoptotic cascades downstream 
of TNF-α signaling pathway. 
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Figure 4.3 Significance of work accomplished 
 
Aim 1 demonstrates on the role of 19S ATPases of the 26S Proteasome in mediating RNA Pol II 
processivity in the transcription elongation of CIITApIV and in regulating transcription of 
CIITApIV genes. Once CIITA is transcribed and translated, CIITA associates with the 
enhanceosome complex along MHCII promoters, and along with histone modifying enzymes 
such as histone acetyl transferases (HATs p300/CBP) and histone methyltransferases (HMTs), is 
recruited to the MHCII promoter and regulates expression of MHCII. This study will provide 
insights into therapeutic strategies for MHCII defective diseases such as Multiple Sclerosis and 
and will also serve as a foundation model to study other inducible genes.     
 
Aim 2 is also focused on the regulation of neuroinflammation but switches to the Regulator of G-
protein signaling 10 (RGS10) and its regulation in microglial cells in response to 
neuroinflammation. RGS10 is abundantly expressed in the brain resident macrophages, or 
microglial cells. Understanding the role of RGS10 in decreasing proinflammatory cytokine 
production in chronically activated microglial cells will aid in developing novel therapeutics 
targets to combat neuroinflammation, not only in Multiple Sclerosis, but also in 
neurodegenerative diseases such as Alzheimer’s and Parkinson’s. 
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